UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K
|
[X]
|
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the fiscal year ended December 31, 2014
|
[ ]
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Commission File No. 0-18105
VASOMEDICAL, INC.
(Exact name of registrant as specified in Its Charter)
|
Delaware
|
11-2871434
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation or organization)
|
Identification No.)
|
|
180 Linden Avenue, Westbury, New York
|
11590
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (516) 997-4600
Securities registered under Section 12(b) of the Act: None
Securities registered under Section 12(g) of the Act:
|
Common Stock, $.001 par value
|
OTCBB
|
|
(Title of Class)
|
Name of each exchange on which registered
|
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) Yes x No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
The aggregate market value of common stock held by non-affiliates was approximately $15.7 million based on the closing sales price of the common stock as quoted on the OTCBB on March 26, 2015.
At March 26, 2015, the number of shares outstanding of the issuer's common stock was 156,142,283.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement in connection with its Annual Meeting of Stockholders to be held in June 2015, to be filed pursuant to Regulation 14A of the Securities Exchange Act of 1934, are incorporated by reference into Part III of this Annual Report on Form 10-K.
[THIS PAGE LEFT INTENTIONALLY BLANK]
VASOMEDICAL, INC.
INDEX TO FORM 10-K
|
2
|
||
|
2
|
||
|
7
|
||
|
12
|
||
|
12
|
||
|
12
|
||
|
13
|
||
|
21
|
||
|
21
|
||
|
22
|
||
|
23
|
||
|
23
|
||
|
25
|
||
|
F-1
|
||
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | F-2 | |
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | F-3 | |
| CONSOLIDATED BALANCE SHEETS | F-4 | |
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | F-5 | |
| CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY | F-6 | |
| CONSOLIDATED STATEMENTS OF CASH FLOWS | F-7 | |
| NOTES TO CONSOLIDATED FINANCIAL STATEMENTS |
F-8
|
|
| EXHIBITS | ||
| Exhibit 31 - Certifications Pursuant to Securities Exchange Act Rule 13A-14(A)/15D-14(A) | ||
| Exhibit 32 - Certification of Periodic Report | ||
1
Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
General Overview
Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been engaged in designing, manufacturing, marketing and supporting EECP® Enhanced External Counterpulsation systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Starting 2010, the Company has been diversifying its business by expanding its offering of medical devices as well as introducing new products and services.
In 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics d/b/a VasoHealthcare, organized a group of medical device sales professionals and entered into the sales representation business as the exclusive representative for the sale of select General Electric Company (GE) diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia.
In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. (LET) and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Biox is a Variable Interest Entity controlled by the Company through certain contracts and an option to acquire all the shares of Biox.
In April 2014, the Company announced that it entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of VSK, which began operations in January 2015.
In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GE Healthcare (GEHC) to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.
In August 2014, the Company acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone). Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.
2
The Company operates through four wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® equipment business as well as other medical equipment operations; and VasoHealthcare IT Corp. conducts our healthcare IT business.
The Company is looking to achieve greater profitability by expanding its U.S. and international market product portfolio. In addition, the Company intends to continue pursuing acquisitions or partnerships and to expand its sales representation business.
Business Segments
We manage and evaluate our operations based on the products and services we offer. Under this approach, we report our financial results through three segments - Sales Representation, Equipment and IT. Our principal manufacturing facilities are located in China.
Sales Representation
The Sales Representation segment currently operates under a sales representative agreement with GE Healthcare (GEHC Agreement), the healthcare business unit of GE, which commenced July 1, 2010. The GEHC Agreement had an initial term of three years. In 2012 the agreement was extended for two additional years, and in December 2014 the agreement was extended again through December 31, 2018, subject to earlier termination under certain circumstances including the right to terminate without cause with certain conditions on or after July 1, 2017. All revenues and expenses in this segment arise through its operations under the GEHC Agreement.
Under the GEHC Agreement, the Company earns commissions based upon achieving certain calendar year targets. Our annual commission rate increases when targets are met as the year progresses, and the increased commission rates are applied retroactively to January 1 of the year. The progressive nature of our agreement can thus result in significantly higher commissions due us in the fourth and first quarters as compared to the second and third quarters of the calendar year.
Equipment
The Equipment segment operates through two subsidiaries: Vasomedical Solutions and Vasomedical Global. The segment is involved in design, manufacture and distribution of medical devices, mainly the Company’s proprietary products such as EECP® systems and Biox™ ambulatory monitoring systems. Vasomedical Solutions markets EECP® therapy systems and other medical equipment in the United States and in select international markets, while engineering development and manufacturing activities are primarily conducted in Vasomedical Global’s facilities in China, which, in addition to being the primary supplier of medical equipment to Vasomedical Solutions, also sells its Biox™ ambulatory monitoring products directly to end users in China and other countries.
IT
The IT segment operates through VasoHealthcare IT Corp. and is principally engaged as a VAR for the sale, implementation, training and ongoing support of GE Healthcare software solutions and related services.
Sales and Marketing
In the Sales Representation segment, we sell GEHC diagnostic imaging products to our assigned market through a nationwide team of sales employees led by a vice president of sales of VasoHealthcare and several regional managers, supported by in-house administrative and other support, as well as applicable GEHC employees.
The sales and marketing efforts of our Equipment segment are led by a vice president of international sales and marketing as well as a vice president of national sales and service at Vasomedical Solutions, who supervises a team of sales managers covering various regions in the United States. We historically market our EECP® systems internationally through distributors in various countries throughout Europe, the Middle East, Africa, Asia and Latin America and the distribution structure is being realigned with our partner’s via the newly formed joint venture VSK Medical. . We sell our Biox™-series ambulatory monitoring systems in China by a group of sales managers as well as through distributors covering various regions of China.
3
The sales and marketing efforts of our IT business is led by a general manager with several software solution sales and implementation specialists. The unit works with our VasoHealthcare diagnostic imaging sales team to generate leads and potential clients for the software solutions products.
Competition
In the U.S. diagnostic imaging market, our main competitors are Siemens, Philips, Toshiba, and Hologic. Key competitive factors in the market include price, quality, delivery speed, service and support, innovation, distribution network, breadth of product and service offerings and brand name recognition. We believe GEHC is a leading competitor in this market.
Though we believe that we are the industry leader of external counterpulsation technology, our competitors in our EECP® business are Renew Group Pte. Ltd and Scottcare Cardiovascular Solutions in the United States, and internationally PSK-Health Sci-Tech Development Co., Ltd., with which we formed a joint venture to co-market external counterpulsation products in the international market.
In the ambulatory monitoring system business, there are numerous competitors of various size and strength. The Biox™ series is among few from China with CE Mark certification, FDA clearances as well as Health Canada listing.
In the IT segment our primary competitors are Agfa Healthcare, McKesson, Philips, Carestream Health and other independent software providers. Key competitive factors are brand recognition, quality, Radiology workflow solutions, scalability and service and support capability. We are able to capitalize on the brand recognition of GEHC, a leader in healthcare software solutions.
Regulations on Medical Devices
As a medical device manufacturer and marketer, we are subject to extensive regulation by numerous government regulatory agencies, including the U. S. FDA and similar foreign agencies. We are required to comply with applicable laws, regulations and standards governing the development, preclinical and clinical testing, manufacturing, quality testing, labeling, promotion, import, export, and distribution of our medical devices.
Compliance with Regulations in the United States
The Company’s has received appropriate US FDA premarket notification (510(k)) clearance for all its products marketed and sold in the United States, including all EECP® therapy systems and Biox™ ambulatory monitoring systems and analysis and report software. We continue to seek US FDA clearance or approval for new products prior to their introduction to the US market.
We are also subject to other US FDA regulations that apply prior to and after a product is commercially released. These include the current Good Manufacturing Practice (cGMP) requirements, set forth in FDA’s Quality System Regulation (QSR), that require manufacturers to have a quality system for the design, manufacture, packaging, labeling, storage, installation and servicing of medical devices intended for commercial distribution in the United States. This regulation covers various areas including management and organization, device design, purchase and handling of components, production and process controls such as those related to buildings and equipment, packaging and labeling control, distribution, installation, complaint handling, corrective and preventive action, servicing, and records. We are subject to periodic and random inspections by the US FDA for compliance with the cGMP requirements and Quality System Regulation.
4
The US FDA also enforces post-marketing controls that include the requirement to submit medical device reports to the agency when a manufacturer becomes aware of information suggesting that any adverse events are related to its marketed products. The FDA relies on medical device reports to identify product problems and utilizes these reports to determine, among other things, whether it should exercise its enforcement powers. The FDA also may require post-market surveillance studies for specified devices.
We are subject to the Federal Food, Drug, and Cosmetic Act’s, or FDCA’s, general controls, including establishment registration, device listing, and labeling requirements. If we fail to comply with any requirements under the FDCA, we, including our officers and employees, could be subject to, among other things, fines, injunctions, civil penalties, and criminal prosecution. We also could be subject to recalls or product corrections, total or partial suspension of production, denial of premarket notification clearance or premarket approval, and rescission or withdrawal of clearances and approvals. Our products could be detained or seized, the FDA could order a recall, repair, replacement, or refund of our devices, and the agency could require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health.
The advertising of our products is subject to regulation by the Federal Trade Commission, or FTC. The FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. Violations of the FTC Act, such as failure to have substantiation for product claims, would subject us to a variety of enforcement actions, including compulsory process, cease and desist orders and injunctions, which can require, among other things, limits on advertising, corrective advertising, consumer redress and restitution, as well as substantial fines or other penalties.
As a medical device sales channel partner and product reseller to healthcare facilities, we are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws.
Foreign Regulation
In most countries to which we seek to export our medical devices, a local regulatory clearance must be obtained. The regulatory review process varies from country to country and can be complex, costly, uncertain, and time-consuming. Vasomedical’s medical devices including EECP® systems and Biox™ products are all manufactured in accordance with ISO 13485, the international standard for medical devices. All our current medical devices have obtained necessary clearances or approvals prior to their release in the appropriate jurisdictions, including CE marking certification for European Union countries, China FDA (CFDA) approval for mainland China, Korean FDA (KFDA) approval for South Korea, Agencia Nacional de Vigilancia Sanitaria (ANVISA) approval for Brazil, and Health Canada license for Canada.
We are also subject to audits by organizations authorized by foreign countries to determine compliance with laws, regulations and standards that apply to the commercialization of our products in those markets. Examples include auditing by a European Union Notified Body organization (authorized by a member state’s Competent Authority) to determine conformity with the Medical Device Directives (MDD) and by an organization authorized by the Canadian government to determine conformity with the Canadian Medical Devices Regulations (CMDR).
There can be no assurance that we will obtain desired foreign authorizations to commercially distribute our products in those markets or that we will comply with all laws, regulations and standards that pertain to our products in those markets. Failure to receive or delays in receipt of such authorizations or determinations of conformity could have a material adverse effect on our financial condition and results of operations.
Patient Privacy
Federal and state laws protect the confidentiality of certain patient health information, including patient records, and restrict the use and disclosure of that protected information. The U.S. Department of Health and Human Services (HHS) published patient privacy rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA privacy rule) and the regulation was finalized in October 2002. Currently, the HIPAA privacy rule affects us only indirectly in that patient data that we access, collect and analyze may include protected health information. Additionally, we have signed some Business Associate Agreements with Covered Entities that contractually bind us to protect private health information, consistent with the HIPAA privacy rule’s requirements. We do not expect the costs and impact of the HIPAA privacy rule to be material to our business.
5
Strategic Objectives
Our short- and long-term plans for the growth of the Company and to increase stockholder value are:
|
a)
|
Maintain and grow our equipment business, by
|
|
i)
|
Continuing to align the cost structure with revenue growth; and
|
|
ii)
|
Increasing our efforts to grow international sales of all our device offerings.
|
|
b)
|
Continue to diversify our product offerings, by
|
|
i)
|
Identifying and introducing other medical device products and opportunities that fit into our target market;
|
|
ii)
|
Working with select partners to develop our medical device OEM business;
|
|
iii)
|
Leveraging on our participation in the healthcare IT field and developing solutions for connected healthcare and telemedicine including remote and home-based patient monitoring; and
|
|
iv)
|
Pursuing accretive acquisitions of and partnerships with medical device manufacturers to expand our product portfolio.
|
|
c)
|
Maintain and improve business performance in our sales representation segment by increasing market penetration of the GE Healthcare product modalities we represent, and possibly building new teams to represent other vendors.
|
|
d)
|
Continue to build the infrastructure for the newly established healthcare IT business and seek partnership and acquisition opportunities for rapid growth.
|
The above-listed strategic objectives are forward-looking statements. We review, modify and change our strategic objectives from time to time based upon changing business conditions. There can be no assurance that we will be able to achieve our strategic objectives and, even if these results are achieved, risks and uncertainties could cause actual results to differ materially from anticipated results. Financial resource availability may reduce our ability to achieve these strategic objectives. Please see the section of this Form 10-K entitled “Risk Factors” for a description of certain risks, among others that may cause our actual results to vary from the forward-looking statements.
Intellectual Properties
We own eleven US patents including eight utility patents and three design patents that expire at various times through 2023. We will from time to time file other patent applications regarding specific enhancements to the current EECP® models, future generation products, and methods of treatment in the future. Moreover, trademarks have been registered for the names “EECP”, “AngioNew”, “Natural Bypass”, “Vasomedical”, “Vasomedical EECP” , “VasoGlobal”, “VasoSolutions” and “VasoHealthcare”.
Through our China-based subsidiaries, we own six utility patents and one design patent and various trademarks. We also own five software copyright certificates in China, related to Holter ECG and ambulatory blood pressure data analysis and reporting.
In addition to other methods of protecting our proprietary technology, know-how and show-how as well as trade secrets, we pursue a policy of seeking patent protection, both in the US and abroad, for our proprietary EECP® technology. We believe that we have a solid patent foundation in the field of external counterpulsation devices and that the number of patents and applications demonstrates our technical leadership, dating back to the mid-1980s. Our patent portfolio focuses on the areas of external counterpulsation control and the overall design and arrangement of the external counterpulsation apparatus, including the console, treatment bed, fluid distribution, and inflatable cuffs. None of our current competitors have a significant patent portfolio in the area of external counterpulsation devices.
There can be no assurance that our patents will not be violated or that any issued patents will provide protection that has commercial significance. As with any patented technology, litigation could be necessary to protect our patent position. Such litigation can be costly and time-consuming, and there can be no assurance that we will be successful. The loss or violation of our EECP® patents and trademarks could have a material adverse effect upon our business.
6
Employees
As of December 31, 2014, we employed 218 full-time persons, of which 23 are employed through our facility in Westbury, New York, 92 through our VasoHealthcare and VasoHealthcare IT subsidiaries, and 103 are in China. None of our employees are represented by a labor union. We believe that our employee relations are good.
The Company also uses several part-time employees and consultants from time to time for various purposes.
Manufacturing
The Company conducts its manufacturing activities primarily through Life Enhancement Technology Co. Ltd. (LET) and Biox Instruments Co. Ltd. (Biox) facilities in China, while maintaining certain manufacturing capability in the Westbury, NY location to satisfy domestic and international needs for the EECP® systems. LET manufactures EECP® systems and Biox manufactures ambulatory monitoring devices and other medical devices.
All manufacturing operations are conducted under the current Good Manufacturing Practice (cGMP) requirements as set forth in the FDA Quality System Regulation as well as ISO 13485 standard, the international quality standard for medical device manufacturers. We are also certified to conform to full quality assurance system requirements of the EU Medical Device Directive and can apply CE marking to all of our current product models. Lastly, we are certified to comply with the requirements of the Canadian Medical Device Regulations (CMDR). All these regulations and standards subject us to inspections to verify compliance and require us to maintain documentation and controls for the manufacturing and quality activities.
We believe our manufacturing capacity and warehouse facility are adequate to meet the current and immediately foreseeable future demand for the production of our medical devices. We believe our suppliers of the other medical devices we distribute or represent are capable of meeting our demand for the foreseeable future.
Investing in our common stock involves risk. You should carefully consider the following information about these risks together with the other information contained in this Annual Report on Form 10-K. If any of the following risks actually occur, our business could be harmed. This could cause the price of our stock to decline, and you may lose part or all of your investment.
Financial Risks
Achieving profitable operations is dependent on several factors.
Our ability to achieve and sustain profitability is dependent on many factors, primarily being the sufficient and timely generation and recognition of revenue in our Sales Representation segment, the success of our marketing, sales and cost reduction efforts in the Equipment segment, as well as the success of our other strategic initiatives, including our China acquisitions.
Risks Related to Our Business
We currently derive the significant amount of our revenue from our agreement with GEHC.
On May 19, 2010, we signed a sales representation agreement with GEHC, the healthcare business unit of the General Electric Company, for the sale of select GEHC diagnostic imaging products. Under the GEHC Agreement, we have been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The GEHC Agreement had an initial term of three years commencing July 1, 2010 and in 2012 was extended for two additional years to June 30, 2015. In December 2014, the agreement was extended again through December 31, 2018, subject to earlier termination under certain circumstances including the right by GEHC to terminate without cause with certain conditions on or after July 1, 2017.
7
A significant amount of our revenue and prior periods net income arise from activities under this contract. Moreover, our growth depends partially on the territories, customer segments and product modalities assigned to us by GEHC, and thus relies on our ability to demonstrate our added value as a channel partner, and maintain a positive relationship with GEHC. There is no assurance that the agreement will be renewed before it expires or terminated prior to its expiration pursuant to its termination provisions. Should GEHC terminate or not renew the agreement, it would have a material adverse effect on our financial condition and results of operations.
We face competition from other companies and technologies.
We compete with other companies that market medical devices in the global medical device marketplace. We do not know whether these companies, or other potential competitors who may be developing medical devices, may succeed in developing technologies or products that are more efficient or effective than those offered by us, and that would render our technology and existing products obsolete or non-competitive. Potential new competitors may also have substantially greater financial, manufacturing and marketing resources than those possessed by us. In addition, other technologies or products may be developed that have an entirely different approach or means of accomplishing the intended purpose of our products. Accordingly, the life cycles of our products are difficult to estimate. To compete successfully, we must keep pace with technological advancements, respond to evolving consumer requirements and achieve market acceptance.
We may not continue to receive necessary FDA clearances or approvals, which could hinder our ability to market and sell our products.
If we modify our medical devices and the modifications significantly affect safety or effectiveness, or if we make a change to the intended use, we will be required to submit a new premarket notification (510(k)) or premarket approval (PMA) application to FDA. We would not be able to market the modified device in the U.S. until FDA issues a clearance for the 510(k).
If we offer new products that require 510(k) clearance or a PMA, we will not be able to commercially distribute those products until we receive such clearance or approval. Regulatory agency approval or clearance for a product may not be received or may entail limitations on the device’s indications for use that could limit the potential market for the product. Delays in receipt of, or failure to obtain or maintain, regulatory clearances and approvals, could delay or prevent our ability to market or distribute our products. Such delays could have a material adverse effect on our equipment business.
If we are unable to comply with applicable governmental regulations, we may not be able to continue certain of our operations.
We also must comply with current Good Manufacturing Practice (cGMP) requirements as set forth in the Quality System Regulation (QSR) to receive FDA approval to market new products and to continue to market current products. The QSR imposes certain procedural and documentation requirements on us with respect to manufacturing and quality assurance activities, including packaging, storage, and record keeping. Our products and activities are subject to extensive, ongoing regulation, including regulation of labeling and promotion activities and adverse event reporting. Also, our FDA registered facilities are subject to inspection by the FDA and other governmental authorities. Any failure to comply with regulatory requirements could delay or prevent our ability to market or distribute our products. Violation of FDA statutory or regulatory requirements could result in enforcement actions, such as voluntary or mandatory recalls, suspension or withdrawal of marketing clearances or approvals, seizures, injunctions, fines, civil penalties, and criminal prosecutions, all of which could have a material adverse effect on our business. Most states also have similar post-market regulatory and enforcement authority for devices.
Our operations in China are also subject to the laws of the People’s Republic of China with which we must be in compliance in order to conduct these operations.
8
We are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws.
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we predict what effect additional governmental regulations or administrative orders, either domestically or internationally, when and if promulgated, would have on our business in the future. We may be slow to adapt, or we may never adapt to changes in existing requirements or adoption of new requirements or policies. We may incur significant costs to comply with laws and regulations in the future or compliance with laws or regulations may create an unsustainable burden on our business.
We have foreign operations and are subject to the associated risks of doing business in foreign countries.
During the years ended December 31, 2014 and 2013, the Company had and continues to have operations in China. Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, and other factors. The occurrence of any of these risks, if severe enough, could have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.
Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions. There are many tax jurisdictions each of which may have changing tax laws. Applicable taxes include value added taxes (VAT), corporate income tax, and social (payroll) taxes. Regulations are often unclear. Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest. These facts create risks for our operations in China.
We may not receive approvals by foreign regulators that are necessary for international sales.
Sales of medical devices outside the United States are subject to foreign regulatory requirements that vary from country to country. Premarket approval or clearance in the United States does not ensure regulatory approval or clearance by other jurisdictions. If we, or any of our international distributors, fail to obtain or maintain required pre-market approvals or fail to comply with foreign regulations, foreign regulatory authorities may require us to file revised governmental notifications, cease commercial sales of our products in the applicable countries or otherwise cure the problem. Such enforcement action by regulatory authorities may be costly.
In order to sell our products within the European Union, we must comply with the European Union’s Medical Device Directive. The CE marking on our products attests to this compliance. Future regulatory changes may limit our ability to use the CE mark, and any new products we develop may not qualify for the CE mark. If we lose this authorization or fail to obtain authorization on future products, we will not be able to sell our products in the European Union.
We depend on suppliers for the supply of certain products.
While we now manufacture our own EECP® product primarily through one of our China based facilities, we still depend on certain independent suppliers for parts, components and certain finished goods. While we do not foresee any difficulties in timely receiving products at competitive prices, the inability of not receiving products in timely fashion or at competitive prices would adversely affect our business. In addition, as a GEHC channel partner, we could be negatively impacted by interruptions or delays to equipment installations, production and quality issues, and other customer concerns related to GEHC.
We depend on management and other key personnel.
We are dependent on a limited number of key management and technical personnel. The loss of one or more of our key employees may harm our business if we are unable to identify other individuals to provide us with similar services. We do not maintain “key person” insurance on any of our employees. In addition, our success depends upon our ability to attract and retain additional highly qualified management, sales, manufacturing and research and development personnel in our various operations. We face competition in our recruiting activities and may not be able to attract or retain qualified personnel.
9
We may not have adequate intellectual property protection.
Our patents and proprietary technology may not be able to prevent competition by others. The validity and breadth of claims in medical technology patents involve complex legal and factual questions. Future patent applications may not be issued, the scope of any patent protection may not exclude competitors, and our patents may not provide competitive advantages to us. Our patents may be found to be invalid and other companies may claim rights in or ownership of the patents and other proprietary rights held or licensed by us. Also, our existing patents may not cover products that we develop in the future. Moreover, when our patents expire, the inventions will enter the public domain. There can be no assurance that our patents will not be violated or that any issued patents will provide protection that has commercial significance. Litigation may be necessary to protect our patent position. Such litigation may be costly and time-consuming, and there can be no assurance that we will be successful in such litigation.
The loss or violation of certain of our patents and trademarks could have a material adverse effect upon our business.
Since patent applications in the United States are maintained in secrecy until such patent applications are issued, our current product development may infringe patents that may be issued to others. If our products were found to infringe patents held by competitors, we may have to modify our products to avoid infringement, and it is possible that our modified products would not be commercially successful.
Risks Related to Our Industry
Our growth could suffer if the markets into which we sell products decline, do not grow as anticipated or experience cyclicality.
Our growth depends in part on the growth of the healthcare markets which we serve. Our quarterly sales and profits depend substantially on the volume and timing of orders installed during the quarter, and the installation of such orders is difficult to forecast. Product demand is dependent upon the customer’s capital spending budget as well as government funding policies, and matters of public policy as well as product and economic cycles that can affect the spending decisions of these entities. These factors could adversely affect our growth, financial position, and results of operations.
Technological change is difficult to predict and to manage.
We face the challenges that are typically faced by companies in the medical device field. Our product line has required, and any future products will require, substantial development efforts and compliance with governmental clearance or approval requirements. We may encounter unforeseen technological or scientific problems that force abandonment or substantial change in the development of a specific product or process.
We are subject to product liability claims and product recalls that may not be covered by insurance.
The nature of our manufacturing operations exposes us to risks of product liability claims and product recalls. Medical devices as complex as ours frequently experience errors or failures, especially when first introduced or when new versions are released.
We currently maintain product liability insurance at $5,000,000 per occurrence and $6,000,000 in the aggregate. Our product liability insurance may not be adequate. In the future, insurance coverage may not be available on commercially reasonable terms, or at all. In addition, product liability claims or product recalls could damage our reputation even if we have adequate insurance coverage.
10
We do not know the effects of healthcare reform proposals.
The healthcare industry is undergoing fundamental changes resulting from political, economic and regulatory influences. In the United States, the Affordable Care Act was adopted which is designed to provide increased access to healthcare for the uninsured, control the escalation of healthcare expenditures within the economy and use healthcare reimbursement policies to balance the federal budget.
We expect that the United States Congress and state legislatures will continue to review and assess the Affordable Care Act as well as various healthcare reform proposals, and public debate of these issues will likely continue. There have been, and we expect that there will continue to be, a number of federal and state proposals to constrain expenditures for medical products and services, which may affect payments for products such as ours. We cannot predict which, if any of such reform proposals will be adopted and when they might be effective, or the effect these proposals may have on our business. Other countries also are considering health reform. Significant changes in healthcare systems could have a substantial impact on the manner in which we conduct our business and could require us to revise our strategies.
Risks Related to our Securities
The application of the "penny stock" rules could adversely affect the market price of our common stock and increase your transaction costs to sell those shares.
As long as the trading price of our common shares is below $5 per share, the open-market trading of our common shares will be subject to the "penny stock" rules. The "penny stock" rules impose additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and have received the purchaser's written consent to the transaction before the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the Securities and Exchange Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability or decrease the willingness of broker-dealers to sell our common shares, and may result in decreased liquidity for our common shares and increased transaction costs for sales and purchases of our common shares as compared to other securities.
Our common stock is subject to price volatility.
The market price of our common stock historically has been and may continue to be highly volatile. Our stock price could be subject to wide fluctuations in response to various factors beyond our control, including, but not limited to:
|
· medical reimbursement;
|
|
· quarterly variations in operating results;
|
|
· announcements of technological innovations, new products or pricing by our competitors;
|
|
· the rate of adoption by physicians of our technology and products in targeted markets;
|
|
· the timing of patent and regulatory approvals;
|
|
· the timing and extent of technological advancements;
|
|
· results of clinical studies;
|
|
· the sales of our common stock by affiliates or other shareholders with large holdings; and
|
|
· general market conditions.
|
Our future operating results may fall below the expectations of securities industry analysts or investors. Any such shortfall could result in a significant decline in the market price of our common stock. In addition, the stock market has experienced significant price and volume fluctuations that have affected the market price of the stock of many medical device companies and that often have been unrelated to the operating performance of such companies. These broad market fluctuations may directly influence the market price of our common stock.
11
We do not intend to pay dividends in the foreseeable future.
We do not intend to pay any cash dividends on our common stock in the foreseeable future.
Additional Information
We are subject to the reporting requirements under the Securities Exchange Act of 1934 and are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports files or furnished pursuant to Section 13(a) or 15(d) of the Securities Act of 1934.
We lease an 18,000 square foot headquarters and manufacturing facility at 180 Linden Avenue, Westbury, New York 11590 under a lease with a term that expires on August 31, 2015. The annual rental expense for the lease is approximately $139,000. We believe that our current facility is adequate for foreseeable current and future needs and that there will be no difficulty in acquiring comparable facilities if we do not extend our current lease. It is currently anticipated that we will be relocating into substantially smaller facilities at a significantly reduced cost.
We also lease approximately 1,500 square feet of office space in New York City under a lease that expires on May 31, 2017. The annual rent and utility charge for this lease is approximately $41,000.
We lease our engineering and production facilities in China. We lease approximately 10,500 square feet under leases expiring in December 2015 and March 2018 at an aggregate annual cost of approximately $55,000 in Wuxi, China and approximately 11,000 square feet under a lease that expires in April 2016 at an annual cost of approximately $34,000 in Foshan, China.
ITEM 5 -- MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock currently trades on OTCBB under the symbol VASO. The number of record holders of common stock as of March 26, 2015, was approximately 940, which does not include approximately 8,500 beneficial owners of shares held in the name of brokers or other nominees. The table below sets forth the range of high and low trade prices of the common stock for the fiscal periods specified.
|
Year ended
December 31, 2014
|
Year ended
December 31, 2013
|
|||||||||||||||
|
High
|
Low
|
High
|
Low
|
|||||||||||||
|
First quarter
|
$ | 0.49 | $ | 0.31 | $ | 0.19 | $ | 0.17 | ||||||||
|
Second quarter
|
$ | 0.36 | $ | 0.25 | $ | 0.19 | $ | 0.17 | ||||||||
|
Third quarter
|
$ | 0.32 | $ | 0.16 | $ | 0.34 | $ | 0.17 | ||||||||
|
Fourth quarter
|
$ | 0.25 | $ | 0.16 | $ | 0.34 | $ | 0.25 | ||||||||
The last bid price of the Company's common stock on March 26, 2015, was $0.17 per share.
Dividend Policy
We have never paid any cash dividends on our common stock and do not intend to pay cash dividends in the foreseeable future.
12
ITEM 7 -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains descriptions of our expectations regarding future trends affecting our business. These forward looking statements and other forward-looking statements made elsewhere in this document are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please read the section titled “Risk Factors” in “Item One – Business” to review certain conditions, among others, which we believe could cause results to differ materially from those contemplated by the forward-looking statements.
Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential”, “intends”, and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
The following discussion should be read in conjunction with the financial statements and notes thereto included in this Annual Report on Form 10-K.
Overview
Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, began its sales representation business via its agreement (GEHC Agreement) with GE Healthcare (GEHC), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances including the right by GEHC to terminate without cause subject to certain conditions on or after July 1, 2017.
In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.
13
In April 2014, the Company announced that it entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The joint venture is in the early implementation phase and began operations in January 2015.
In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.
In August 2014, the Company acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone). Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.
We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT operations report under the IT segment.
The Company continues to pursue acquisitions or partnership opportunities in the international and domestic markets and to seek expansion of its sales representation business.
Results of Operations – For the Years Ended December 31, 2014 and 2013
Net revenues increased by $2,064,000, or 6%, to $34,954,000 in the year ended December 31, 2014, from $32,890,000 in the year ended December 31, 2013. We reported net income of $1,128,000 for the year ended December 31, 2014 as compared to a net loss of $1,145,000 for the year ended December 31, 2013, an increase of $2,273,000. Our net income was $0.01 per basic and diluted common share for the year ended December 31, 2014 as compared to a net loss of $0.01 per basic and diluted common share for the year ended December 31, 2013.
Revenues
Commission revenues in the Sales Representation segment increased by $3,608,000, or 14%, to $30,236,000 in the year ended December 31, 2014, as compared to $26,628,000 in the year ended December 31, 2013. The increase was primarily the combined results of higher volume of GEHC equipment delivery in 2014 and higher commission rates for the equipment delivered in 2014. As discussed in Note B to the financial statements, the Company defers recognition of commission revenue until the underlying equipment is delivered. As of December 31, 2014, the Company recorded a 27% increase in deferred commission revenue, to $21,155,000, of which $12,006,000 is long-term, compared to $16,666,000 in deferred commission revenue at December 31, 2013 of which $6,852,000 was long-term.
Revenue in our Equipment segment decreased 25% to $4,670,000, including $1,741,000 in revenue from FGE, for the year ended December 31, 2014 from $6,262,000, including $1,938,000 in FGE revenue, for the year ended December 31, 2013. Equipment segment revenue from equipment sales decreased by $1,340,000, or 29%, to $3,233,000 for the year ended December 31, 2014 as compared to $4,573,000 for the year ended December 31, 2013. The decrease in equipment sales is due primarily to a $1,121,000 decrease in EECP® sales, driven by lower deliveries, partially offset by higher average selling prices, as well as a $197,000 decrease in sales by FGE.
Equipment segment revenue from equipment rentals and services decreased 15% to $1,437,000 in the year ended December 31, 2014 from $1,689,000 in the year ended December 31, 2013. Revenue from equipment rentals and services represented 31% of total Equipment segment revenue in the year ended December 31, 2014 and 27% in the year ended December 31, 2013. The decrease in revenue generated from equipment rentals and services is due primarily to decreased contract product development and service contract revenues, partially offset by higher field service revenues.
14
We recorded revenue from our new IT segment of $48,000 during the year ended December 31, 2014. We anticipate significant growth in this business segment in future periods.
Gross Profit
The Company recorded gross profit of $25,192,000, or 72% of revenue, for the year ended December 31, 2014 compared to $22,513,000, or 68% of revenue, for the year ended December 31, 2013. The increase of $2,679,000 was due primarily to a $3,363,000 increase in the Sales Representation segment, driven by both higher revenues and gross profit rates, partially offset by $705,000 lower gross profit in the Equipment segment resulting from a mix of lower revenues and higher gross profit rates.
Sales Representation segment gross profit was $22,251,000, or 74% of Sales Representation segment revenues, for the year ended December 31, 2014, an increase of $3,363,000, or 18%, from segment gross profit of $18,888,000, or 71% of segment revenue, for the year ended December 31, 2013. The increase in gross profit was due primarily to higher recognized revenue in 2014 as a result of higher equipment delivery volume as well as higher commission rates. Cost of commissions increased by $245,000, or 3%, to $7,985,000 for the year ended December 31, 2014, as compared to cost of commissions of $7,740,000 in 2013. Cost of commissions reflects commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
Equipment segment gross profit decreased to $2,920,000, or 63% of Equipment segment revenues, for the year ended December 31, 2014 compared to $3,625,000, or 58% of Equipment segment revenues, for the year ended December 31, 2013 due to lower sales volume partially offset by improved margins resulting from higher mix of FGE operations. Equipment segment gross profits are dependent on a number of factors including the mix of EECP® products and ambulatory monitoring devices, the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the ongoing costs of servicing EECP® systems, as well as certain fixed period costs, including facilities, payroll and insurance.
Operating Income (Loss)
Operating income was $1,063,000 for the year ended December 31, 2014 compared to a loss of $1,290,000 for the year ended December 31, 2013, an improvement of $2,353,000. The increase was primarily attributable to the increase in operating income in the Sales Representation segment from $2,475,000 in the year ended December 31, 2013 to $5,997,000 in that segment in the year ended December 31, 2014. The 2014 Sales Representation segment operating income reflected the impact of both higher commission rates and lower SG&A costs. Equipment segment operating loss in the year ended December 31, 2014 was $2,828,000, as compared to an operating loss of $2,418,000 in the year ended December 31, 2013. The increase in the Equipment segment operating loss was primarily due to lower gross profit, partially offset by lower SG&A costs.
Selling, general and administrative (SG&A) expenses for the years ended December 31, 2014 and 2013 were $23,326,000, or 67% of revenues, and $23,114,000, or 70% of revenues, respectively, reflecting an increase of $212,000 or approximately 1%. The increase in SG&A expenditures in the year ended December 31, 2014 resulted primarily from $558,000 in costs incurred in the newly formed IT segment, which began operations in the third quarter of 2014, and higher corporate expenses, partially offset by lower sales and marketing costs in the Equipment and Sales Representation segments.
Research and development (R&D) expenses of $803,000, or 2% of revenues (or 17% of Equipment segment revenues), for the year ended December 31, 2014 increased by $114,000, or 17%, from $689,000, or 2% of revenues (or 11% of Equipment segment revenues), for the year ended December 31, 2013. The increase is primarily attributable to an increase in clinical grants.
Other Income and Expense, Net
Interest and other income, net of other expense, for the year ended December 31, 2014 and 2013, was $192,000 and $87,000, respectively, an increase of $105,000. The increase was due primarily to a one-time $130,000 charge in 2013 to settle the Company’s liability to a workers’ compensation fund arising from the bankruptcy in 2007 of a trade association that previously provided workers’ compensation for the Company and other members of the association, partially offset by lower interest income earned on the Company’s cash balances and lower government grants obtained by one of the Company’s Chinese companies.
15
Income Tax Benefit (Expense), Net
During the year ended December 31, 2014, we recorded income tax expense of $127,000, as compared to an income tax benefit of $58,000 in the year ended December 31, 2013. The Company utilized $3.0 million and $0 in net operating loss carryforwards for the years ended December 31, 2014 and 2013, respectively. Income tax expense increased mainly due to a Federal tax refund recognized in 2013.
Ultimate realization of any or all of the deferred tax assets is not assured due to significant uncertainties and material assumptions associated with estimates of future taxable income during the carry-forward period. The Company believes it is premature to recognize additional deferred tax assets based on such uncertainties.
Liquidity and Capital Resources
Cash and Cash Flow – For the year ended December 31, 2014
At December 31, 2014, we had cash and cash equivalents of $9,128,000, short-term investments of $111,000 and working capital of $9,215,000.
Cash provided by operating activities was $2,594,000 during the year ended December 31, 2014, which consisted of net income after non-cash adjustments of $1,960,000 and cash provided by changes in operating assets and liabilities of $634,000. The changes in the account balances primarily reflect an increase in deferred revenue of $4,513,000, partially offset by an increase in accounts and other receivables of $1,671,000 and an increase in other assets of $2,505,000. These changes in account balances are due mainly to the operations of our Sales Representation segment. At March 26, 2014 the Company’s cash balances were approximately $15.9 million.
Cash used in investing activities during the year ended December 31, 2014 was $1,388,000, consisting of $1,023,000 used for the acquisition of Genwell net of cash acquired, and $365,000 for net purchases of equipment and software.
Cash used in financing activities during the year ended December 31, 2014 was $46,000, consisting of $245,000 for the repurchase of common stock, partially offset by $36,000 provided by the exercise of stock options and $163,000 provided by a term loan entered into by one of our Chinese companies.
Liquidity
While the Company was profitable in fiscal 2014, it has historically incurred operating losses and incurred losses for the years ended December 31, 2013 and 2012. The Company expects to continue to be profitable through GEHC’s higher delivery volume of equipment booked with our Sales Representation segment, the expected growth in our IT segment and through growth in our China operations, and by expanding our product portfolio. In addition, the Company plans to pursue other accretive acquisitions and partnerships in the international and domestic markets and to expand our sales representation business.
While we expect to generate positive operating cash flows in fiscal 2015, the progressive nature of the GEHC Agreement can cause related cash inflows to vary widely during the year.
Based on our operations through December 31, 2014 and our current business outlook for 2015, we believe internally generated funds from our Equipment and Sales Representation segments will be sufficient for the Company to continue operations through at least January 1, 2016.
16
Off-Balance Sheet Arrangements
We do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPES), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December 31, 2014, we are not involved in any unconsolidated SPES or other off-balance sheet arrangements.
Related Party Transactions
David Lieberman, a practicing attorney in the State of New York, serves as Vice Chairman of the Board of Directors. He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $240,000 and $247,000 were billed by the firm for the years ended December 31, 2014 and 2013, respectively, at which dates no amounts were outstanding.
At December 31, 2014 and 2013, $3,000 in unsecured loans were payable to the president of LET and $21,000 in advances were due from officers of FGE. These loans and advances are short term and do not bear interest.
On August 6, 2014 the Company acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone) for cash and notes of Chinese Yuan RMB13,250,000 (approximately $2,151,000 at the acquisition date). Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system. The president of our subsidiary Life Enhancement Technologies Ltd. and the president and vice-president of Biox Instruments Company Ltd. together owned 80.9% of Genwell at the time of acquisition. The President and CEO of the Company was appointed the nominee Chairman of Genwell at its formation for the sole purpose of applying for the government grant available only to overseas Chinese persons. He has never received any compensation from Genwell nor held any ownership interest in Genwell. The Company has received a fairness opinion for this transaction from an independent certified appraisal firm and a legal opinion from Chinese counsel. At December 31, 2014, unsecured notes and accrued interest aggregating $1,036,000 are payable to the president of Life Enhancement Technologies Ltd. and the president of Biox Instruments Company Ltd.
Effects of Inflation
We believe that inflation and changing prices over the past two years have not had a significant impact on our revenue or on our results of operations.
Critical Accounting Policies and Estimates
Note B of the Notes to Consolidated Financial Statements includes a summary of our significant accounting policies and methods used in the preparation of our financial statements. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. Our critical accounting policies are as follows:
Revenue Recognition
We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.
Revenue and Expense Recognition for the Sales Representation Segment
We recognize commission revenue in its Sales Representation segment when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the Consolidated Balance Sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized
17
Revenue and Expense Recognition for the Equipment Segment
In the United States, we recognize revenue from the sale of our medical equipment in the period in which we deliver the product to the customer. Revenue from the sale of our medical equipment to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered to both domestic and international customers. Returns are accepted prior to the in-service and training subject to a 10% restocking charge or for normal warranty matters, and we are not obligated for post-sale upgrades to these systems. In addition, we use the installment method to record revenue based on cash receipts in situations where the account receivable is collected over an extended period of time and in our judgment the degree of collectability is uncertain.
In most cases, revenue from domestic EECP® system sales is generated from multiple-element arrangements that require judgment in the areas of customer acceptance, collectability, the separability of units of accounting, and the fair value of individual elements. We follow the FASB Accounting Standards Codification (“ASC”) Topic 605 “Revenue Recognition” (“ASC 605”) which outlines a framework for recognizing revenue from multi-deliverable arrangements. The principles and guidance outlined in ASC 605 provide a framework to determine (a) how the arrangement consideration should be measured (b) whether the arrangement should be divided into separate units of accounting, and (c) how the arrangement consideration should be allocated among the separate units of accounting. We determined that the domestic sale of our EECP® systems includes a combination of three elements that qualify as separate units of accounting:
|
· EECP® equipment sale;
|
|
· provision of in-service and training support consisting of equipment set-up and training provided at the customer’s facilities; and
|
|
· a service arrangement (usually one year), consisting of: service by factory-trained service representatives, material and labor costs, emergency and remedial service visits, software upgrades, technical phone support and preferred response times.
|
Each of these elements represent individual units of accounting as the delivered item has value to a customer on a stand-alone basis, objective and reliable evidence of fair value exists for undelivered items, and arrangements normally do not contain a general right of return relative to the delivered item. We determine fair value based on the price of the deliverable when it is sold separately, or based on third-party evidence, or based on estimated selling price. Assuming all other criteria for revenue recognition have been met, we recognize revenue for:
|
· EECP® equipment sales, when title transfers upon delivery;
|
|
· in-service and training, following documented completion of the training; and
|
|
· service arrangement, ratably over the service period, which is generally one year.
|
In-service and training generally occurs within a few weeks of shipment and our return policy states that no returns will be accepted after in-service and training has been completed. The amount related to in-service and training is recognized as service revenue at the time the in-service and training is completed and the amount related to service arrangements is recognized ratably as service revenue over the related service period, which is generally one year. Costs associated with the provision of in-service and training and the service arrangement, including salaries, benefits, travel, spare parts and equipment, are recognized in cost of equipment sales as incurred.
The Company also recognizes revenue generated from servicing EECP® systems that are no longer covered by the service arrangement, or by providing sites with additional training, in the period that these services are provided. Revenue related to future commitments under separately priced extended service agreements on our EECP® system are deferred and recognized ratably over the service period, generally ranging from one year to four years. Costs associated with the provision of service and maintenance, including salaries, benefits, travel and spare parts, and equipment, are recognized in cost of services as incurred. Amounts billed in excess of revenue recognized are included as deferred revenue in the consolidated balance sheets.
18
Revenues from the sale of EECP® systems through our international distributor network are generally covered by a one-year warranty period. For these customers we accrue a warranty reserve for estimated costs to provide warranty parts when the equipment sale is recognized.
Revenue and Expense Recognition for the IT Segment
We recognize revenue and related costs in the IT segment when services are completed and equipment, if any, is delivered.
Accounts Receivable, net
Accounts receivable are due from customers engaged in the provision of medical services and from GEHC. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and are stated at amounts due from customers net of allowances for doubtful accounts, returns, term discounts and commission adjustments. Accounts that remain outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for doubtful accounts based on the Company’s historical collections experience, current trends, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, we look at historical write-offs of our receivables. The Company also looks at the credit quality of their customer base as well as changes in their credit policies. The Company continuously monitors collections and payments from our customers, and writes off receivables when all efforts at collection have been exhausted. While credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that they have in the past.
Inventories, net
We value inventory at the lower of cost or estimated market, with cost being determined on a first-in, first-out basis. The Company often places EECP® systems and other medical device products at various field locations for demonstration, training, evaluation, and other similar purposes at no charge. The cost of these EECP® systems and other products is transferred to property and equipment and is amortized over the next two to five years. The Company records the cost of refurbished components of EECP® systems and critical components at cost plus the cost of refurbishment. The Company regularly reviews inventory quantities on hand, particularly raw materials and components, and records a provision for excess and obsolete inventory based primarily on existing and anticipated design and engineering changes to its products as well as forecasts of future product demand.
We comply with the provisions of ASC Topic 330, “Inventory”. The statement clarifies that abnormal amounts of idle facility expense, freight, handling costs, and wasted materials (spoilage) should be recognized as current-period charges and requires the allocation of fixed production overheads to inventory based on the normal capacity of the production facilities.
Deferred Revenues
We record revenue on extended service contracts ratably over the term of the related contract period. In accordance with the provisions of ASC Topic 605, we defer revenue related to EECP® system sales for the fair value of installation and in-service training to the period when the services are rendered and for warranty obligations ratably over the service period, which is generally one year.
Amounts billable under the agreement with GE Healthcare in advance of customer acceptance of the equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC.
19
Warranty Costs
Equipment sold is generally covered by a warranty period of one year. Under the provisions of ASC Topic 605, for certain arrangements, a portion of the overall system price attributable to the first year service arrangement is deferred and recognized as revenue over the service period. As such, we do not accrue warranty costs upon delivery but rather we recognize warranty and related service costs as incurred.
Equipment sold to international customers through our distributor network is generally covered by a one-year warranty period. For these customers the Company accrues an allowance for estimated warranty costs of providing a parts-only warranty when the equipment sale is recognized.
The factors affecting our warranty liability included the number of units sold and historical and anticipated rates of claims and costs per claim.
Net Income (Loss) per Common Share
Basic income (loss) per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted income (loss) per share is based on the weighted number of common and potential dilutive common shares outstanding. The calculation takes into account the shares that may be issued upon the exercise of stock options and warrants, reduced by the shares that may be repurchased with the funds received from the exercise, based on the average price during the period. Options and warrants to purchase shares of common stock, as well as unvested common stock grants, are excluded from the computation of diluted earnings per share should the effect of their inclusion be anti-dilutive.
Income Taxes
Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry forwards for which income tax benefits are expected to be realized in future years. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future events other than an enactment of changes in the tax laws or rates. Deferred tax assets are continually evaluated for realizability. To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate as to the realizability of the assets changed that it is “more likely than not” that all of the deferred tax assets will be realized. The “more likely than not” standard is subjective and is based upon our estimate of a greater than 50% probability that the deferred tax asset will be realized.
Deferred tax assets and liabilities are classified as current or non-current based on the classification of the related asset or liability for financial reporting. A deferred tax asset or liability that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.
We also comply with the provisions of the ASC Topic 740, “Income Taxes”, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Based on its analysis, except for certain liabilities assumed in the FGE acquisition, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of December 31, 2014 and December 31, 2013. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2014 and December 31, 2013. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.
Share-based Employee Compensation
We comply with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all companies to recognize the cost of services received in exchange for equity instruments, to be recognized in the financial statements based on their fair values. For purposes of estimating the fair value of each option on the date of grant, the Company utilizes the Black-Scholes option-pricing model.
20
Equity instruments issued to non-employees in exchange for goods, fees and services are accounted for under the fair value-based method of ASC Topic 505 “Equity” (ASC 505).
Recently Issued Accounting Pronouncements
Standards Issued not yet adopted
In May 2014, the FASB issued ASU 2014-09 “Revenue from contracts with customers”, a comprehensive new revenue recognition standard which will supersede previous existing revenue recognition guidance. The standard creates a five-step model for revenue recognition that requires companies to exercise judgment when considering contract terms and relevant facts and circumstances. The five-step model includes (1) identifying the contract, (2) identifying the separate performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations and (5) recognizing revenue when each performance obligation has been satisfied. The standard also requires expanded disclosures surrounding revenue recognition. The standard is effective for fiscal periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption.
The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.
ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements listed in the accompanying Index to Consolidated Financial Statements are filed as part of this report.
ITEM 9A - CONTROLS AND PROCEDURES
Report on Disclosure Controls and Procedures
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2014 and have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2014.
Management’s Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control involves maintaining records that accurately represent our business transactions, providing reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization, and providing reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be detected or prevented on a timely basis.
21
Because of its innate limitations, internal control over our financial statements is not intended to provide absolute guarantee that a misstatement can be detected or prevented on the statements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in condition, or that the degree of compliance with the policies or procedures may deteriorate.
Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 COSO framework). A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Based on this evaluation and those criteria, the Company’s CEO and CFO concluded that the Company’s internal control over financial reporting was effective as of December 31, 2014.
This report does not include an attestation report of the Company’s Independent Registered Public Accounting Firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s Independent Registered Public Accounting Firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only Management’s report in this Annual Report.
Changes in Internal Control over Financial Reporting
For the quarter ended December 31, 2014 there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
The information required by Part III is intended to be included in our definitive Proxy Statement, which will be filed with the Securities and Exchange Commission in connection with our 2015 Annual Meeting of Stockholders and is incorporated herein by reference.
22
ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Financial Statements and Financial Statement Schedules
|
(1) See Index to Consolidated Financial Statements on page F-1 at beginning of attached financial statements.
|
|
(a)
|
Exhibits
|
|
(2)
|
(a)
|
Restated Certificate of Incorporation (2)
|
|
(b)
|
By-Laws (1)
|
|
|
(3.1)
|
Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (9)
|
|
|
(4)
|
(a)
|
Specimen Certificate for Common Stock (1)
|
|
(b)
|
Specimen Certificate for Series E Convertible Preferred Stock (11)
|
|
|
(10)
|
(a)
|
1995 Stock Option Plan (3)
|
|
(b)
|
Outside Director Stock Option Plan (3)
|
|
|
(c)
|
1997 Stock Option Plan, as amended (4)
|
|
|
(d)
|
1999 Stock Option Plan, as amended (5)
|
|
|
(e)
|
2004 Stock Option/Stock Issuance Plan (6)
|
|
|
(f)
|
Securities Purchase Agreement dated June 21, 2007 between Registrant and Kerns Manufacturing Corp. (7)
|
|
|
(g)
|
Form of Common Stock Purchase Warrant to dated June 21, 2007 (7)
|
|
|
(h)
|
Registration Rights Agreement dated June 21, 2007 between Registrant, Kerns Manufacturing Corp. and Living Data Technology Corporation. (7)
|
|
|
(i)
|
Purchase and Sale Agreement dated June 1, 2007 between 180 Linden Avenue Corp and 180 Linden Realty LLC. (8)
|
|
|
(j)
|
Lease Agreement dated August 15, 2007 between 180 Linden Realty LLC and Registrant (8)
|
|
|
(k)
|
Form of Stock Purchase Agreement (9)
|
|
|
(l)
|
Redacted Sales Representative Agreement between GE Healthcare Division of General Electric Company and Vaso Diagnostics, Inc. d/b/a VasoHealthcare, a subsidiary of Vasomedical, Inc. dated as of May 19, 2010 (10).
|
|
|
(m)
|
2010 Stock Plan (11).
|
|
|
(n)
|
Consulting Agreement dated March 1, 2011 between Vasomedical, Inc. and Edgary Consultants, LLC. (12)
|
|
|
(o)
|
Employment Agreement entered into as of March 21, 2011 between Vasomedical, Inc. and Jun Ma, as amended. (15)
|
|
|
(p)
|
Stock Purchase Agreement dated as of August 19, 2011 among Vasomedical, Inc., Fast Growth Enterprises Limited (FGE) and the FGE Shareholders (13)
|
|
|
(q)
|
Amendment to Sales Representative Agreement between GE Healthcare Division of General Electric Company and Vaso Diagnostics, Inc. d/b/a VasoHealthcare, a subsidiary of Vasomedical, Inc. dated as of June 20, 2012 (14)
|
(21) Subsidiaries of the Registrant
|
Name
|
State of Incorporation
|
Percentage Owned by Company
|
|
Viromedics, Inc.
|
Delaware
|
61%
|
|
Vaso Diagnostics, Inc.
|
New York
|
100%
|
|
Vasomedical Global Corp
|
New York
|
100%
|
|
Vasomedical Solutions, Inc.
|
New York
|
100%
|
| VasoHealthcare IT Corp. | Delaware | 100% |
|
Fast Growth Enterprises Limited
|
British Virgin Islands
|
100%
|
| VSK Medical Limited | Cayman Islands | 49.9% |
|
(31)
|
Certification Reports pursuant to Securities Exchange Act Rule 13a - 14 | |
|
(32)
|
Certification Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
23
__________________________
(1) Incorporated by reference to Registration Statement on Form S-18, No. 33-24095.
|
(2)
|
Incorporated by reference to Registration Statement on Form S-1, No. 33-46377 (effective 7/12/94).
|
|
(3)
|
Incorporated by reference to Report on Form 8-K dated January 24, 1995.
|
|
(4)
|
Incorporated by reference to Report on Form 10-K for the fiscal year ended May 31, 1999
|
|
(5)
|
Incorporated by reference to Report on Form 10-K for the fiscal year ended May 31, 2000.
|
|
(6)
|
Incorporated by reference to Notice of Annual Meeting of Stockholders dated October 28, 2004.
|
|
(7)
|
Incorporated by reference to Report on Form 8-K dated June 21, 2007.
|
|
(8)
|
Incorporated by reference to Report on Form 10-KSB for the fiscal year ended May 31, 2007.
|
|
(9)
|
Incorporated by reference to Report on Form 8-K dated June 21, 2010.
|
|
(10)
|
Incorporated by reference to Report on Form 8-K/A dated May 29, 2010 and filed November 9, 2010.
|
|
(11)
|
Incorporated by reference to Report on Form 10-K for the fiscal year ended May 31, 2010.
|
|
(12)
|
Incorporated by reference to Report on Form 8-K dated March 4, 2011.
|
|
(13)
|
Incorporated by reference to Report on Form 10-K for the fiscal year ended May 31, 2011.
|
|
(14)
(15)
|
Incorporated by reference to Report on Form 8-K dated June 20, 2012.
Incorporated by reference to Report on Form 10-K dated December 31, 2012.
|
24
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 27th day of March, 2015.
|
VASOMEDICAL, INC.
|
||
|
By: /s/ Jun Ma
|
||
|
Jun Ma
|
||
|
President, Chief Executive Officer,
|
||
|
and Director (Principal Executive Officer)
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 27, 2015, by the following persons in the capacities indicated:
|
/s/ Jun Ma
|
President, Chief Executive Officer and Director
|
|
Jun Ma
|
(Principal Executive Officer)
|
|
/s/ Michael Beecher
|
Chief Financial Officer (Principal Financial Officer)
|
|
Michael Beecher
|
|
|
/s/ Simon Srybnik
|
Chairman of the Board
|
|
Simon Srybnik
|
|
|
/s/ David Lieberman
|
Vice Chairman of the Board
|
|
David Lieberman
|
|
| /s/ Randy Hill | Senior Vice President and Director |
| Randy Hill | |
|
/s/ Edgar Rios
|
Director
|
|
Edgar Rios
|
|
|
/s/ Behnam Movaseghi
|
Director
|
|
Behnam Movaseghi
|
|
|
/s/ Peter C. Castle
|
Director
|
|
Peter C. Castle
|
|
25
Vasomedical, Inc. and Subsidiaries
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
For the years ended December 31, 2014 and 2013
|
Page
|
|
|
Report of Independent Registered Public Accounting Firm
|
F-2
|
| Report of Independent Registered Public Accounting Firm | F-3 |
|
Financial Statements
|
|
|
Consolidated Balance Sheets as of December 31, 2014 and 2013
|
F-4
|
|
Consolidated Statements of Operations and Comprehensive Income (Loss)
|
|
|
for the years ended December 31, 2014 and 2013
|
F-5 |
|
Consolidated Statements of Changes in Stockholders’ Equity
|
|
|
for the years ended December 31, 2014 and 2013
|
F-6 |
|
Consolidated Statements of Cash Flows
|
|
|
for the year ended December 31, 2014 and 2013
|
F-7 |
|
Notes to Consolidated Financial Statements
|
F-8 – F-31
|
F-1
To the Audit Committee of the
Board of Directors and Stockholders
of Vasomedical, Inc.
We have audited the accompanying consolidated balance sheet of Vasomedical, Inc. and Subsidiaries (the “Company”) as of December 31, 2014, and the related consolidated statements of operations and comprehensive income, changes in stockholders’ equity and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Vasomedical, Inc. and Subsidiaries, as of December 31, 2014, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.
/s/ Marcum LLP
Marcum llp
Melville, NY
March 30, 2015
F-2
To the Board of Directors and Stockholders of
Vasomedical, Inc.
We have audited the accompanying consolidated balance sheet of Vasomedical, Inc. and Subsidiaries (collectively, the “Company”) as of December 31, 2013, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ equity, and cash flows for the year ended December 31, 2013. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2013, and the results of its operations and its cash flows for the year ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America.
/s/ Rothstein Kass
New York, New York
March 27, 2014
F-3
Vasomedical, Inc. and Subsidiaries
(in thousands, except share and per share data)
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
ASSETS
|
||||||||
|
CURRENT ASSETS
|
||||||||
|
Cash and cash equivalents
|
$ | 9,128 | $ | 7,961 | ||||
|
Short-term investments
|
111 | 111 | ||||||
|
Accounts and other receivables, net of an allowance for doubtful
|
||||||||
|
accounts and commission adjustments of $4,571 at December 31,
|
||||||||
|
2014 and $3,764 at December 31, 2013
|
15,273 | 13,570 | ||||||
|
Receivables due from related parties
|
21 | 21 | ||||||
|
Inventories, net
|
1,898 | 1,618 | ||||||
|
Deferred commission expense
|
2,200 | 2,312 | ||||||
|
Prepaid expenses and other current assets
|
363 | 338 | ||||||
|
Total current assets
|
28,994 | 25,931 | ||||||
|
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
|
||||||||
|
$1,397 at December 31, 2014 and $1,281 at December 31, 2013
|
266 | 365 | ||||||
|
GOODWILL
|
3,288 | 3,303 | ||||||
| INTANGIBLES, net | 2,826 | 820 | ||||||
|
OTHER ASSETS
|
5,617 | 3,098 | ||||||
| $ | 40,991 | $ | 33,517 | |||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
CURRENT LIABILITIES
|
||||||||
|
Accounts payable
|
$ | 462 | $ | 597 | ||||
|
Accrued commissions
|
2,247 | 2,161 | ||||||
|
Accrued expenses and other liabilities
|
5,583 | 5,571 | ||||||
|
Sales tax payable
|
247 | 230 | ||||||
|
Income taxes payable
|
44 | - | ||||||
|
Deferred revenue - current portion
|
9,882 | 10,541 | ||||||
|
Notes payable
|
163 | - | ||||||
|
Deferred tax liability, net
|
112 | 112 | ||||||
|
Notes payable due to related party
|
1,039 | 3 | ||||||
|
Total current liabilities
|
19,779 | 19,215 | ||||||
|
LONG-TERM LIABILITIES
|
||||||||
|
Deferred revenue
|
12,650 | 7,478 | ||||||
|
Other long-term liabilities
|
811 | 359 | ||||||
|
Total long-term liabilities
|
13,461 | 7,837 | ||||||
|
COMMITMENTS AND CONTINGENCIES (NOTE R)
|
||||||||
|
STOCKHOLDERS' EQUITY
|
||||||||
|
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
|
||||||||
|
issued and outstanding at December 31, 2014, and December 31, 2013
|
- | - | ||||||
|
Common stock, $.001 par value; 250,000,000 shares authorized;
|
||||||||
|
166,435,370 and 164,705,382 shares issued at December 31, 2014 outstanding
|
||||||||
|
and December 31, 2013, respectively; 156,127,283 and
|
||||||||
|
155,223,981 shares outstanding at December 31, 2014 and
|
||||||||
|
December 31, 2013, respectively
|
166 | 165 | ||||||
|
Additional paid-in capital
|
61,924 | 61,508 | ||||||
|
Accumulated deficit
|
(52,433 | ) | (53,561 | ) | ||||
|
Accumulated other comprehensive income
|
94 | 108 | ||||||
|
Treasury stock, at cost, 10,308,087 and 9,481,401 shares at December 31, 2014 and
December 31, 2013, respectively
|
(2,000 | ) | (1,755 | ) | ||||
|
Total stockholders’ equity
|
7,751 | 6,465 | ||||||
| $ | 40,991 | $ | 33,517 | |||||
The accompanying notes are an integral part of these consolidated financial statements.
F-4
Vasomedical, Inc. and Subsidiaries
|
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
|
(in thousands, except per share data)
| Year ended | ||||||||
| December 31, | ||||||||
|
2014
|
2013
|
|||||||
|
Revenues
|
||||||||
|
Commissions
|
$ | 30,236 | $ | 26,628 | ||||
|
Equipment sales
|
3,233 | 4,573 | ||||||
|
Equipment rentals and services
|
1,437 | 1,689 | ||||||
|
IT systems
|
48 | - | ||||||
|
Total revenues
|
34,954 | 32,890 | ||||||
|
Cost of revenues
|
||||||||
|
Cost of commissions
|
7,985 | 7,740 | ||||||
|
Cost of equipment sales
|
1,027 | 1,785 | ||||||
|
Cost of equipment rentals and services
|
723 | 852 | ||||||
|
Cost of IT systems
|
27 | - | ||||||
|
Total cost of revenues
|
9,762 | 10,377 | ||||||
|
Gross profit
|
25,192 | 22,513 | ||||||
|
Operating expenses
|
||||||||
|
Selling, general and administrative
|
23,326 | 23,114 | ||||||
|
Research and development
|
803 | 689 | ||||||
|
Total operating expenses
|
24,129 | 23,803 | ||||||
|
Operating income (loss)
|
1,063 | (1,290 | ) | |||||
|
Other income (expense)
|
||||||||
|
Interest and other income, net
|
207 | 87 | ||||||
|
Loss on disposal of fixed assets
|
(15 | ) | - | |||||
|
Total other income, net
|
192 | 87 | ||||||
|
Income (loss) before income taxes
|
1,255 | (1,203 | ) | |||||
|
Income tax benefit (expense)
|
(127 | ) | 58 | |||||
|
Net income (loss)
|
1,128 | (1,145 | ) | |||||
|
Other comprehensive income
|
||||||||
|
Foreign currency translation (loss) gain
|
(14 | ) | 74 | |||||
|
Comprehensive income (loss)
|
$ | 1,114 | $ | (1,071 | ) | |||
|
Income (loss) per common share
|
||||||||
|
- basic
|
$ | 0.01 | $ | (0.01 | ) | |||
|
- diluted
|
$ | 0.01 | $ | (0.01 | ) | |||
|
Weighted average common shares outstanding
|
||||||||
|
- basic
|
155,362 | 159,377 | ||||||
|
- diluted
|
156,032 | 159,377 | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-5
Vasomedical, Inc. and Subsidiaries
|
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
|
(in thousands)
| Accumulated | |||||||||||||||||||||||||
| Common Stock | Treasury Stock | Additional Paid-in |
Accumulated
|
Other Comprehensive
|
Total Stockholders'
|
||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Income
|
Equity
|
||||||||||||||||||
|
Balance at December 31, 2012
|
162,918 | $ | 163 | - | $ | - | $ | 61,229 | $ | (52,416 | ) | $ | 34 | $ | 9,010 | ||||||||||
|
Repurchase of
Shares
|
- | - | (9,481) | (1,755) | - | - | - | (1,755) | |||||||||||||||||
|
Share-based
compensation
|
1,787 | 2 | - | - | 367 | - | - | 369 | |||||||||||||||||
|
Shares not issued
for employee tax
liability
|
- | - | - | - | (88 | ) | - | - | (88 | ) | |||||||||||||||
|
Foreign currency
translation gain (loss)
|
- | - | - | - | - | - | 74 | 74 | |||||||||||||||||
|
Net loss
|
- | - | - | - | - | (1,145 | ) | - | (1,145 | ) | |||||||||||||||
|
Balance at December 31, 2013
|
164,705 | 165 | (9,481) | (1,755) | 61,508 | (53,561 | ) | 108 | 6,465 | ||||||||||||||||
|
Repurchase of
shares
|
- | - | (827 | ) | (245 | ) | - | - | - | (245 | ) | ||||||||||||||
|
Share-based
compensation
|
1,280 | 1 | - | - | 389 | - | - | 390 | |||||||||||||||||
|
Shares not issued
for employee tax
liability
|
- | - | - | - | (9 | ) | - | - | (9 | ) | |||||||||||||||
| Exercise of stock options | 450 | - | - | - | 36 | - | - | 36 | |||||||||||||||||
|
Foreign currency
translation gain (loss)
|
- | - | - | - | - | - | (14) | (14) | |||||||||||||||||
|
Net income
|
- | - | - | - | - | 1,128 | - | 1,128 | |||||||||||||||||
|
Balance at December 31, 2014
|
166,435 | $ | 166 | (10,308) | ) | $ | (2,000 | ) | $ | 61,924 | $ | (53,433 | ) | $ | 94 | $ | 7,751 | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-6
Vasomedical, Inc. and Subsidiaries
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(in thousands)
| Year ended | ||||||||
| December 31, | ||||||||
|
2014
|
2013
|
|||||||
|
Cash flows from operating activities
|
||||||||
|
Net income (loss)
|
$ | 1,128 | $ | (1,145 | ) | |||
|
Adjustments to reconcile net income (loss) to net cash
|
||||||||
|
provided by (used in) operating activities
|
||||||||
|
Depreciation and amortization
|
467 | 361 | ||||||
|
Loss on disposal of fixed assets
|
15 | - | ||||||
|
Provision for doubtful accounts and commission adjustments
|
(40 | ) | 42 | |||||
|
Share-based compensation and arrangements
|
390 | 456 | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts and other receivables
|
(1,671 | ) | (4,547 | ) | ||||
|
Receivables due from related parties
|
- | 5 | ||||||
|
Inventories, net
|
(294 | ) | 545 | |||||
|
Deferred commission expense
|
112 | 168 | ||||||
|
Other current assets
|
(25 | ) | (103 | ) | ||||
|
Other assets
|
(2,505 | ) | (945 | ) | ||||
|
Accounts payable
|
(135 | ) | 255 | |||||
|
Accrued commissions
|
86 | (177 | ) | |||||
|
Accrued expenses and other liabilities
|
18 | 925 | ||||||
|
Sales tax payable
|
18 | 52 | ||||||
|
Income taxes payable
|
44 | (1 | ) | |||||
|
Deferred revenue
|
4,513 | 2,417 | ||||||
|
Notes payable due to related party
|
20 | - | ||||||
|
Other long-term liabilities
|
453 | 188 | ||||||
|
Net cash provided by (used in) operating activities
|
2,594 | (1,504 | ) | |||||
|
Cash flows from investing activities
|
||||||||
|
Purchases of equipment and software
|
(389 | ) | (228 | ) | ||||
|
Sale of fixed assets
|
24 | - | ||||||
|
Purchases of short-term investments
|
(111 | ) | (111 | ) | ||||
|
Redemption of short-term investments
|
111 | 111 | ||||||
|
Acquisition of Genwell
|
(1,136 | ) | - | |||||
|
Cash acquired through purchase of Genwell
|
113 | - | ||||||
|
Net cash used in investing activities
|
(1,388 | ) | (228 | ) | ||||
|
Cash flows from financing activities
|
||||||||
|
Proceeds from exercise of stock options
|
36 | - | ||||||
|
Repurchase of common stock
|
(245 | ) | (1,755 | ) | ||||
|
Proceeds from note payable
|
163 | - | ||||||
|
Net cash used in financing activities
|
(46 | ) | (1,755 | ) | ||||
|
Effect of exchange rate differences on cash and cash equivalents
|
7 | (21 | ) | |||||
|
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
1,167 | (3,508 | ) | |||||
|
Cash and cash equivalents - beginning of year
|
7,961 | 11,469 | ||||||
|
Cash and cash equivalents - end of year
|
$ | 9,128 | $ | 7,961 | ||||
|
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
|
||||||||
|
Interest paid
|
$ | 1 | $ | - | ||||
|
Income taxes paid
|
$ | 48 | $ | 69 | ||||
|
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
|
||||||||
|
Inventories transferred to property and equipment,
|
||||||||
|
attributable to operating leases, net
|
$ | 6 | $ | 25 | ||||
|
Assets acquired through issuance of note
|
$ | 1,017 | $ | - | ||||
The accompanying notes are an integral part of these consolidated financial statements.
F-7
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE A – DESCRIPTION OF BUSINESS AND LIQUIDITY
Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.
In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd.(Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.
In April 2014, the Company announced that it entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the joint venture, which is in the early implementation phase and began operations in January 2015.
In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.
In August 2014, the Company acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone). Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.
We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT operations report under the IT segment.
While the Company returned to profitability in fiscal 2014, it has historically incurred operating losses and incurred losses for the years ended December 31, 2013 and 2012. The Company believes it will achieve continued profitability through GEHC's higher delivery volume of equipment booked with our Sales Representation segment, the expected growth in our IT segment and through growth in our China operations, and by expanding our product portfolio. In addition, the Company plans to pursue other accretive acquisitions and partnerships in the international and domestic markets and to expand our sales representation business.
F-8
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
A summary of the significant accounting policies consistently applied in the preparation of the consolidated financial statements are as follows:
Principles of Consolidation
The consolidated financial statements include the accounts of Vasomedical, Inc., its wholly-owned subsidiaries, its inactive majority-owned subsidiary, and variable interest entities where the Company is the primary beneficiary. Significant intercompany accounts and transactions have been eliminated.
Variable Interest Entity
Basic Information
The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities.
Biox is a Variable Interest Entity (VIE). Laws and regulations of the Peoples Republic of China (PRC) prohibit or restrict companies with foreign ownership from certain activities and benefits including eligibility for PRC government technology development grants. To provide the Company the expected residual returns of the VIE, the Company, through its subsidiary Gentone, entered into a series of contractual arrangements with Biox and its registered shareholders to enable the Company, to:
-
exercise effective control over the VIE;
-
receive substantially all of the economic benefits and residual returns, and absorb substantially all the risks of the VIE as if they were their sole shareholders; and
-
have an exclusive option to purchase all of the equity interests in the VIE.
The Company’s management evaluated the relationships between the Company and Biox, and the economic benefits flow of the applicable contractual arrangements. The Company concluded that it is the primary beneficiary of Biox. As a result, the results of operations, assets and liabilities of Biox have been included in the Company’s consolidated financial statements.
The significant agreements through which the Company exercises effective control over Biox are:
-
the Exclusive Technical Consulting Services Agreement between Biox and Gentone;
-
the Option Agreement on Purchase of the Equity Interest executed by and among the shareholders of Biox and Gentone;
-
the Equity Pledge Agreement executed by and among the shareholders of Biox and Gentone; and
-
the Powers of Attorney issued by the shareholders of Biox.
Financial Information of VIE
Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which was included in the accompanying consolidated financial statements, is presented as follows:
| (In thousands) | ||||||||
| As of December 31, | ||||||||
|
2014
|
2013
|
|||||||
|
Cash and cash equivalents
|
$ | 159 | $ | 469 | ||||
|
Total assets
|
$ | 1,047 | $ | 1,237 | ||||
|
Total liabilities
|
$ | 878 | $ | 690 | ||||
F-9
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
| (In thousands) | ||||||||
| Year ended December 31, | ||||||||
|
2014
|
2013
|
|||||||
|
Total net revenue
|
$ | 1,741 | $ | 1,928 | ||||
|
Net (loss) income
|
$ | (373 | ) | $ | 204 | |||
Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of collectibility of accounts receivable, the realizability of deferred tax assets, stock-based compensation, values and lives assigned to acquired intangible assets, the adequacy of inventory and warranty reserves, and allocation of fair value among the elements of the multi-deliverable arrangements. Additionally, significant estimates and assumptions impact the Company’s accounting relative to its business combination. Actual results could differ from those estimates.
Revenue Recognition
The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.
Revenue and Expense Recognition for the Sales Representation Segment
The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the Consolidated Balance Sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized
Revenue and Expense Recognition for the Equipment Segment
We recognize revenue from the sale of equipment in the period in which we deliver the equipment to the customer. Revenue from the sale of our equipment to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered to both domestic and international customers. Returns are accepted prior to the in-service and training, subject to a 10% restocking charge, or for normal warranty matters, and we are not obligated for post-sale upgrades to these systems. In addition, we use the installment method to record revenue based on cash receipts in situations where the account receivable is collected over an extended period of time and in our judgment the degree of collectability is uncertain.
In most cases, revenue from domestic EECP® system sales is generated from multiple-element arrangements that require judgment in the areas of customer acceptance, collectability, the separability of units of accounting, and the fair value of individual elements. We follow the FASB Accounting Standards Codification (“ASC”) Topic 605 “Revenue Recognition” (“ASC 605”) which outlines a framework for recognizing revenue from multi-deliverable arrangements. The principles and guidance outlined in ASC 605 provide a framework to determine (a) how the arrangement consideration should be measured (b) whether the arrangement should be divided into separate units of accounting, and (c) how the arrangement consideration should be allocated among the separate units of accounting. We determined that the domestic sale of our EECP® systems includes a combination of three elements that qualify as separate units of accounting:
F-10
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
|
· EECP® equipment sale;
|
|
· provision of in-service and training support consisting of equipment set-up and training provided at the customer’s facilities; and
|
|
· a service arrangement (usually one year), consisting of: service by factory-trained service representatives, material and labor costs, emergency and remedial service visits, software upgrades, technical phone support and preferred response times.
|
Each of these elements represent individual units of accounting as the delivered item has value to a customer on a stand-alone basis, objective and reliable evidence of fair value exists for undelivered items, and arrangements normally do not contain a general right of return relative to the delivered item. We determine fair value based on the price of the deliverable when it is sold separately, or based on third-party evidence, or based on estimated selling price. Assuming all other criteria for revenue recognition have been met, we recognize revenue for:
|
· EECP® equipment sales, when title transfers upon delivery;
|
|
· in-service and training, following documented completion of the training; and
|
|
· service arrangement, ratably over the service period, which is generally one year.
|
In-service and training generally occurs within a few weeks of shipment and our return policy states that no returns will be accepted after in-service and training has been completed. The amount related to in-service and training is recognized as service revenue at the time the in-service and training is completed and the amount related to service arrangements is recognized ratably as service revenue over the related service period, which is generally one year. Costs associated with the provision of in-service and training and the service arrangement, including salaries, benefits, travel, spare parts and equipment, are recognized in cost of equipment sales as incurred.
The Company also recognizes revenue generated from servicing EECP® systems that are no longer covered by the service arrangement, or by providing sites with additional training, in the period that these services are provided. Revenue related to future commitments under separately priced extended service agreements on our EECP® system are deferred and recognized ratably over the service period, generally ranging from one year to five years. Costs associated with the provision of service and maintenance, including salaries, benefits, travel and spare parts, and equipment, are recognized in cost of equipment rentals and services as incurred. Amounts billed in excess of revenue recognized are included as deferred revenue in the Consolidated Balance Sheets.
Revenues from the sale of EECP® systems through our international distributor network are generally covered by a one-year warranty period. For these customers we accrue a warranty reserve for estimated costs to provide warranty parts when the equipment sale is recognized.
Revenue and Expense Recognition for the IT Segment
The Company recognizes revenue and related costs in the IT segment when services are completed and equipment, if any, is delivered.
Shipping and Handling Costs
All shipping and handling expenses are charged to cost of sales. Amounts billed to customers related to shipping and handling costs are included as a component of sales.
Research and Development
Research and development costs attributable to development are expensed as incurred. Included in research and development costs is amortization expense related to the capitalized cost of EECP® systems under loan for clinical trials.
F-11
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Share-Based Compensation
The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all companies to recognize the cost of services received in exchange for equity instruments, to be recognized in the financial statements based on their fair values. For purposes of estimating the fair value of each option on the date of grant, the Company utilizes the Black-Scholes option-pricing model. Equity instruments issued to non-employees in exchange for goods, fees and services are accounted for under the fair value-based method of ASC Topic 505 “Equity” (ASC 505).
During the year ended December 31, 2014, the Company granted 230,000 restricted shares of common stock valued at $49,100 to non-officer employees, vesting at various periods through September 2017; 450,000 restricted shares of common stock valued at $157,500 to officers, vesting at various periods through February 2016; and 500,000 restricted shares of common stock valued at $175,000 to directors, which vested immediately. The total fair value of shares vested during the year ended December 31, 2014 was $376,000 for employees.
During the year ended December 31, 2013, the Company granted 385,000 restricted shares of common stock valued at $91,700 to non-officer employees, vesting at various periods through June 2015, and granted 100,000 restricted shares of common stock valued at $18,000 to an officer, which vested immediately. The total fair value of shares vested during the year ended December 31, 2013 was approximately $730,000 for employees and approximately $4,000 for non-employees.
The Company did not grant any stock options during the years ended December 31, 2014 or 2013. The intrinsic value of options exercised during the years ended December 31, 2014 and 2013 was $58,500 and $0, respectively.
Share-based compensation expense recognized for the years ended December 31, 2014 and 2013 was $390,000 and $369,000, respectively. Expense for other share-based arrangements was $0 and $87,000 for the years ended December 31, 2014 and 2013, respectively. Unrecognized expense related to existing share-based compensation and arrangements is approximately $77,000 at December 31, 2014 and will be recognized over a period of approximately 1.5 years.
Cash and Cash Equivalents
Cash and cash equivalents represent cash and short-term, highly liquid investments either in certificates of deposit, treasury bills, money market funds, or investment grade commercial paper issued by major corporations and financial institutions that generally have maturities of three months or less from the date of acquisition. Dividend and interest income are recognized when earned. The cost of securities sold is calculated using the specific identification method.
Short-Term Investments
The Company’s short-term investments consist of certificates of deposit with original maturities greater than three months and up to one year that are held to maturity.
Accounts Receivable, net
The Company’s accounts receivable are due from customers engaged in the distribution of our products and customers engaged in the provision of medical services and from GEHC. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and services provided and are stated at amounts due from customers net of allowances for doubtful accounts, returns, term discounts and other allowances. Accounts that are outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for doubtful accounts based on the Company’s historical collections experience, current trends, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, the Company reviews historical write-offs of their receivables. The Company also looks at the credit quality of their customer base as well as changes in their credit policies. The Company continuously monitors collections and payments from our customers, and writes off receivables when all efforts at collection have been exhausted. While credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that they have in the past.
F-12
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The changes in the Company’s allowance for doubtful accounts and commission adjustments are as follows:
| (in thousands) | ||||||||
|
For the year ended
|
For the year ended
|
|||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Beginning Balance
|
$ | 3,764 | $ | 3,179 | ||||
|
Provision for losses on accounts receivable
|
11 | 68 | ||||||
|
Direct write-offs, net of recoveries
|
(156 | ) | - | |||||
|
Commission adjustments
|
952 | 517 | ||||||
|
Ending Balance
|
$ | 4,571 | $ | 3,764 | ||||
Concentrations of Credit Risk
We market our equipment and IT solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years ended December 31, 2014 and 2013, no customer in our Equipment or IT segments accounted for 10% or more of revenues or accounts receivable. In our Sales Representation segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position.
The Company maintains cash balances in certain U.S. financial institutions, which, at times, may exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000. The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $410,000 and $701,000 at December 31, 2014 and 2013, respectively.
Inventories, net
The Company values inventory at the lower of cost or estimated market, with cost being determined on a first-in, first-out basis. The Company often places EECP® systems at various field locations for demonstration, training, evaluation, and other similar purposes at no charge. The cost of these EECP® systems is transferred to property and equipment and is amortized over two to five years. The Company records the cost of refurbished components of EECP® systems and critical components at cost plus the cost of refurbishment. The Company regularly reviews inventory quantities on hand, particularly raw materials and components, and records a provision for excess and obsolete inventory based primarily on existing and anticipated design and engineering changes to its products as well as forecasts of future product demand.
We comply with the provisions of ASC Topic 330 “Inventory”. The statement clarifies that abnormal amounts of idle facility expense, freight, handling costs, and wasted materials (spoilage) should be recognized as current-period charges and requires the allocation of fixed production overhead to inventory based on the normal capacity of the production facilities.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized and minor replacements, maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheets. Depreciation is expensed over the estimated useful lives of the assets, which range from two to eight years, on a straight-line basis. Accelerated methods of depreciation are used for tax purposes. We amortize leasehold improvements over the useful life of the related leasehold improvement or the life of the related lease, whichever is less.
F-13
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Goodwill and Intangible Assets
Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350 – “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance. The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The impairment test is based on the estimated fair value of the underlying businesses and performed in the fourth quarter of each year. Intangible assets consist of patent and technology costs, customer lists and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives, which range from 5 to 10 years. The Company capitalizes internal use software costs incurred during the application development stage. Costs related to preliminary project activities and post implementation activities are expensed as incurred. The Company capitalized $263,000 and $155,000 in software development costs for the years ended December 31, 2014 and 2013, respectively.
Impairment of Long-lived Assets
The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated fair value determined by either the undiscounted future net cash flows or appraised value to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. No assets were determined to be impaired as of December 31, 2014 and 2013.
Deferred Revenue
We record revenue on extended service contracts ratably over the term of the related service contracts. Under the provisions of ASC 605, we began to defer revenue related to EECP® system sales for the fair value of installation and in-service training to the period when the services are rendered and for service obligations ratably over the service period, which is generally one year. (See Note J)
Amounts billable under the agreement with GEHC in advance of customer acceptance of the equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC.
Warranty Costs
Equipment sold is generally covered by a warranty period of one year. In accordance with ASC Topic 450 “Loss Contingencies”, we accrue a warranty reserve for estimated costs of providing a parts only warranty when the equipment sale is recognized.
The factors affecting our warranty liability include the number of units sold and the historical and anticipated rates of claims and costs per claim. (See Note K)
Income Taxes
Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry-forwards for which income tax benefits are expected to be realized in future years. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future events other than an enactment of changes in the tax laws or rates. Deferred tax assets are continually evaluated for the expected realization. To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate as to the realization of the assets changed that it is “more likely than not” that all of the deferred tax assets will be realized. The “realization” standard is subjective and is based upon our estimate of a greater than 50% probability that the deferred tax asset can be realized.
F-14
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Deferred tax assets and liabilities are classified as current or non-current based on the classification of the related asset or liability for financial reporting. A deferred tax asset or liability that is not related to an asset or liability for financial reporting, including deferred tax assets related to carry-forwards, are classified according to the expected reversal date of the temporary difference.
The Company also complies with the provisions of ASC Topic 740 “Income Taxes”, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by the relevant taxing authority based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant taxing authority. Derecognition of a tax benefit previously recognized results in the Company recording a tax liability that reduces ending retained earnings. Based on its analysis, except for certain liabilities assumed in the FGE acquisition, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of December 31, 2014 and December 31, 2013. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2014 and December 31, 2013. Generally, the Company is no longer subject to income tax examinations by major domestic taxing authorities for years before 2011. According to the China tax regulatory framework, there is no statute of limitations on examination of tax filings by tax authorities. However, the general practice is going back five years. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.
Foreign Currency Translation Gain (Loss) and Comprehensive Income (Loss)
In countries in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Equity accounts are translated at historical rates except for the changes in retained earnings during the year which is the result of the income statement translation process. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income on the accompanying consolidated balance sheet. For the years ended December 31, 2014 and 2013, comprehensive income (loss) includes (losses) gains of ($14,000) and $74,000, respectively, which were entirely from foreign currency translation.
Fair Value of Financial Instruments
The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:
Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 securities. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.
F-15
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term maturities of the instruments.
Net Income (Loss) Per Common Share
Basic income (loss) per common share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per common share is based on the weighted number of common and potential dilutive common shares outstanding.
Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:
| (in thousands) | ||||||||
|
Year ended
December 31,
|
Year ended
December 31,
|
|||||||
|
2014
|
2013
|
|||||||
|
Basic weighted average shares outstanding
|
155,362 | 159,377 | ||||||
|
Dilutive effect of share-based compensation and options
|
670 | - | ||||||
|
Diluted weighted average shares outstanding
|
156,032 | 159,377 | ||||||
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the years ended December 31, 2014 and 2013, because the effect of their inclusion would be anti-dilutive.
| (in thousands) | ||||||||
|
Year ended
December 31,
|
Year ended
December 31,
|
|||||||
|
2014
|
2013
|
|||||||
|
Stock options
|
52 | 1,780 | ||||||
|
Common stock grants
|
- | 660 | ||||||
| 52 | 2,440 | |||||||
Reclassifications
Certain reclassifications have been made to prior year amounts to conform with the current year presentation.
Recently Issued Accounting Pronouncements
The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. New pronouncements assessed by the Company recently are discussed below:
F-16
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Standards Issued not yet adopted
In May 2014, the FASB issued ASU 2014-09 “Revenue from contracts with customers”, a comprehensive new revenue recognition standard which will supersede previous existing revenue recognition guidance. The standard creates a five-step model for revenue recognition that requires companies to exercise judgment when considering contract terms and relevant facts and circumstances. The five-step model includes (1) identifying the contract, (2) identifying the separate performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations and (5) recognizing revenue when each performance obligation has been satisfied. The standard also requires expanded disclosures surrounding revenue recognition. The standard is effective for fiscal periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption.
The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.
NOTE C – SEGMENT REPORTING
The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment. The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices. The Company’s new subsidiary, VasoHealthcare IT Corp., formed to conduct its healthcare IT operations, reports through the IT segment. Operations in the IT segment began in the third quarter of 2014. The chief operating decision maker is the Company’s Chief Executive Officer, who in conjunction with upper management, evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:
| (in thousands) | ||||||||||||||||||||
| As of or for the year ended December 31, 2014 | ||||||||||||||||||||
|
Sales Representation Segment
|
Equipment Segment
|
IT Segment
|
Corporate
|
Consolidated
|
||||||||||||||||
|
Revenues from external customers
|
$ | 30,236 | $ | 4,670 | $ | 48 | $ | - | $ | 34,954 | ||||||||||
|
Operating income (loss)
|
$ | 5,997 | $ | (2,828 | ) | $ | (539 | ) | $ | (1,567 | ) | $ | 1,063 | |||||||
|
Total assets
|
$ | 21,966 | $ | 10,012 | $ | 61 | $ | 8,952 | $ | 40,991 | ||||||||||
|
Accounts and other receivables, net
|
$ | 14,306 | $ | 915 | $ | 52 | $ | - | $ | 15,273 | ||||||||||
|
Deferred commission expense
|
$ | 2,200 | $ | - | $ | - | $ | - | $ | 2,200 | ||||||||||
|
Other assets
|
$ | 4,888 | $ | 716 | $ | - | $ | 13 | $ | 5,617 | ||||||||||
| As of or for the year ended December 31, 2013 | ||||||||||||||||||||
|
Sales Representation Segment
|
Equipment Segment
|
IT Segment
|
Corporate
|
Consolidated
|
||||||||||||||||
|
Revenues from external customers
|
$ | 26,628 | $ | 6,262 | $ | - | $ | - | $ | 32,890 | ||||||||||
|
Operating income (loss)
|
$ | 2,475 | $ | (2,418 | ) | $ | - | $ | (1,347 | ) | $ | (1,290 | ) | |||||||
|
Total assets
|
$ | 18,085 | $ | 7,907 | $ | - | $ | 7,525 | $ | 33,517 | ||||||||||
|
Accounts and other receivables, net
|
$ | 12,637 | $ | 933 | $ | - | $ | - | $ | 13,570 | ||||||||||
|
Deferred commission expense
|
$ | 2,312 | $ | - | $ | - | $ | - | $ | 2,312 | ||||||||||
|
Other assets
|
$ | 2,659 | $ | 426 | $ | - | $ | 13 | $ | 3,098 | ||||||||||
F-17
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the years ended December 31. 2014 and 2013, GEHC accounted for 87% and 81% of revenue, respectively. Also, GEHC accounted for $14.2 million, or 93%, and $12.5 million, or 92%, of accounts and other receivables at December 31, 2014 and December 31, 2013, respectively.
Our revenues were derived from the following geographic areas:
| (in thousands) | ||||||||
|
For the year ended
|
For the year ended
|
|||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Domestic (United States)
|
$ | 32,905 | $ | 29,431 | ||||
|
Non-domestic (foreign)
|
2,049 | 3,459 | ||||||
| $ | 34,954 | $ | 32,890 | |||||
NOTE D – FAIR VALUE MEASUREMENTS
The Company’s assets recorded at fair value have been categorized based upon a fair value hierarchy in accordance with ASC 820.
The following table presents information about the Company’s assets measured at fair value as of December 31, 2014:
| (in thousands) | ||||||||||||||||
|
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
|
Significant
Other
Observable
Inputs
(Level 2)
|
Significant
Unobservable
Inputs
(Level 3)
|
Balance
as of
December 31,
2014
|
|||||||||||||
|
Assets
|
||||||||||||||||
|
Cash equivalents invested in money market funds (included in cash and cash equivalents)
|
$ | 8,149 | $ | - | $ | - | $ | 8,149 | ||||||||
The following table presents information about the Company’s assets measured at fair value as of December 31, 2013:
| (in thousands) | ||||||||||||||||
|
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1) |
Significant
Other
Observable
Inputs
(Level 2) |
Significant
Unobservable
Inputs
(Level 3) |
Balance
as of
December 31,
2013 |
|||||||||||||
|
Assets
|
||||||||||||||||
|
Cash equivalents invested in money market funds (included in cash and cash equivalents)
|
$ | 6,883 | $ | - | $ | - | $ | 6,883 | ||||||||
The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.
F-18
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE E – ACCOUNTS AND OTHER RECEIVABLES
The following table presents information regarding the Company’s accounts and other receivables as of December 31, 2014 and 2013:
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Trade receivables
|
$ | 19,734 | $ | 17,173 | ||||
|
Due from employees
|
110 | 161 | ||||||
|
Allowance for doubtful accounts and
|
||||||||
|
commission adjustments
|
(4,571 | ) | (3,764 | ) | ||||
|
Accounts and other receivables, net
|
$ | 15,273 | $ | 13,570 | ||||
Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from estimated future changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees primarily reflects commission advances made to sales personnel.
NOTE F – INVENTORIES, NET
Inventories, net of reserves consisted of the following:
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Raw materials
|
$ | 583 | $ | 790 | ||||
|
Work in process
|
679 | 291 | ||||||
|
Finished goods
|
636 | 537 | ||||||
| $ | 1,898 | $ | 1,618 | |||||
At December 31, 2014 and 2013, the Company maintained reserves for slow moving and obsolete inventories of $815,000 and $803,000, respectively.
F-19
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE G – PROPERTY AND EQUIPMENT
Property and equipment is summarized as follows:
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Office, laboratory and other equipment
|
$ | 1,114 | $ | 1,049 | ||||
|
EECP® systems under operating leases
|
||||||||
|
or under loan for clinical trials
|
376 | 369 | ||||||
|
Furniture and fixtures
|
173 | 228 | ||||||
| 1,663 | 1,646 | |||||||
|
Less: accumulated depreciation
|
(1,397 | ) | (1,281 | ) | ||||
|
Property and equipment, net
|
$ | 266 | $ | 365 | ||||
Depreciation expense amounted to approximately $187,000 and $213,000 for the years ended December 31, 2014 and 2013, respectively.
NOTE H – GOODWILL AND OTHER INTANGIBLES
All goodwill is attributable to the Equipment segment. The change in the carrying amount of goodwill was as follows:
| (in thousands) | ||||
|
Carrying Amount
|
||||
|
Balance at December 31, 2013
|
$ | 3,303 | ||
|
Foreign currency translation
|
(15 | ) | ||
|
Balance at December 31, 2014
|
$ | 3,288 | ||
The Company’s other intangible assets consist of capitalized patent and technology costs, customer lists, and software costs, as set forth in the following:
F-20
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Patents and Technology
|
||||||||
|
Costs
|
$ | 2,489 | $ | 469 | ||||
|
Accumulated amortization
|
(549 | ) | (454 | ) | ||||
| 1,940 | 15 | |||||||
|
Customer lists
|
||||||||
|
Costs
|
800 | 800 | ||||||
|
Accumulated amortization
|
(381 | ) | (267 | ) | ||||
| 419 | 533 | |||||||
|
Software
|
||||||||
|
Costs
|
962 | 696 | ||||||
|
Accumulated amortization
|
(495 | ) | (424 | ) | ||||
| 467 | 272 | |||||||
| $ | 2,826 | $ | 820 | |||||
The Company owns eleven US patents including eight utility and three design patents that expire at various times through 2023, and, through our Chinese subsidiaries, six utility patents and one design patent expiring at various times through 2027. Costs incurred for submitting the applications to the United States Patent and Trademark Office and other foreign authorities for these patents have been capitalized. Patent and technology costs are being amortized using the straight-line method over 10-year and 8-year lives, respectively. The Company begins amortizing patent costs once a filing receipt is received stating the patent serial number and filing date from the Patent Office or other foreign authority. Customer lists and software are amortized on a straight-line basis over their expected useful lives of seven and five years, respectively.
Amortization expense amounted to approximately $280,000 and $169,000 for the years ended December 31, 2014 and 2013, respectively. Amortization of intangibles for the next five years is:
| (in thousands) | ||||||||||||||||||||
|
2015
|
2016
|
2017
|
2018
|
2019
|
||||||||||||||||
|
Amortization expense
|
$ | 483 | $ | 488 | $ | 476 | $ | 432 | $ | 282 | ||||||||||
NOTE I – OTHER ASSETS
Other assets consist of the following at December 31, 2014 and 2013:
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Deferred commission expense - noncurrent
|
$ | 2,988 | $ | 1,667 | ||||
|
Trade receivables - noncurrent
|
2,171 | 1,181 | ||||||
|
Other
|
458 | 250 | ||||||
| $ | 5,617 | $ | 3,098 | |||||
F-21
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE J – DEFERRED REVENUE
The changes in the Company’s deferred revenues are as follows:
| (in thousands) | ||||||||
|
For the year ended
|
For the year ended
|
|||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Deferred revenue at the beginning of the year
|
$ | 18,019 | $ | 15,602 | ||||
|
Additions:
|
||||||||
|
Deferred extended service contracts
|
912 | 1,048 | ||||||
|
Deferred in-service and training
|
40 | 33 | ||||||
|
Deferred service arrangements
|
88 | 96 | ||||||
|
Deferred commission revenues
|
17,992 | 14,495 | ||||||
|
Recognized as revenue:
|
||||||||
|
Deferred extended service contracts
|
(869 | ) | (991 | ) | ||||
|
Deferred in-service and training
|
(50 | ) | (28 | ) | ||||
|
Deferred service arrangements
|
(96 | ) | (74 | ) | ||||
|
Deferred commission revenues
|
(13,504 | ) | (12,162 | ) | ||||
|
Deferred revenue at end of year
|
22,532 | 18,019 | ||||||
|
Less: current portion
|
9,882 | 10,541 | ||||||
|
Long-term deferred revenue at end of year
|
$ | 12,650 | $ | 7,478 | ||||
NOTE K – ACCRUED EXPENSES AND OTHER LIABILITIES
Accrued expenses and other liabilities consist of the following at December 31, 2014 and 2013:
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Accrued compensation
|
$ | 2,915 | $ | 2,123 | ||||
|
Accrued expenses - other
|
1,098 | 1,982 | ||||||
|
Other liabilities
|
1,570 | 1,466 | ||||||
| $ | 5,583 | $ | 5,571 | |||||
Included in other liabilities is the Company’s product warranty liability. Changes in product warranty liability are as follows:
| (in thousands) | ||||||||
| For the year ended December 31, | ||||||||
|
2014
|
2013
|
|||||||
|
Warranty liability at the beginning of the year
|
$ | 33 | $ | 26 | ||||
|
Expense for new warranties issued
|
8 | 57 | ||||||
|
Warranty claims
|
(38 | ) | (50 | ) | ||||
|
Warranty liability at the end of the year
|
3 | 33 | ||||||
|
Long-term warranty liability at the end of the year
|
$ | - | $ | - | ||||
NOTE L – RELATED-PARTY TRANSACTIONS
David Lieberman, a practicing attorney in the State of New York, serves as Vice Chairman of the Board of Directors. He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $240,000 and $247,000 were billed by the firm for the years ended December 31, 2014 and 2013, respectively, at which dates no amounts were outstanding.
F-22
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
At December 31, 2014 and 2013, $3,000 in unsecured loans were payable to an employee of LET and $21,000 in advances were due from employees of FGE. These loans and advances are short term and do not bear interest.
On August 6, 2014 the Company acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone) for cash and notes of Chinese Yuan RMB13,250,000 (approximately $2,151,000 at the acquisition date – see Note P). Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system. The president of our subsidiary Life Enhancement Technologies Ltd. and the president and vice-president of Biox Instruments Company Ltd. together owned 80.9% of Genwell at the time of acquisition. The President and CEO of the Company was appointed the nominee Chairman of Genwell at its formation for the sole purpose of applying for the government grant available only to overseas Chinese persons. He has never received any compensation from Genwell nor held any ownership interest in Genwell. The Company has received a fairness opinion for this transaction from an independent certified appraisal firm and a legal opinion from Chinese counsel. At December 31, 2014, unsecured notes and accrued interest aggregating $1,036,000 are payable to the president of Life Enhancement Technologies Ltd. and the president of Biox Instruments Company Ltd.
NOTE M– DEBT
In November 2014, Biox entered into an unsecured term loan of Chinese Yuan RMB1,000,000 (approximately $163,000) with a Chinese bank. The loan term is one year and bears interest at 6.72%, payable monthly.
NOTE N– STOCKHOLDERS' EQUITY
Common stock
In April 2013, the Company’s Board of Directors authorized a share repurchase program of up to $1.5 million, which was subsequently increased in July 2013 to $2.0 million, of the Company’s common stock. During the years ended December 31, 2014 and 2013, the Company repurchased 826,686 shares at a cost of $245,000 and 9,481,401 shares at a cost of $1,755,000, respectively, which cost has been recorded as treasury stock in the accompanying consolidated balance sheets as of December 31, 2014 and 2013.
In December 2014, 250,000 shares were issued to an officer and 200,000 shares were issued to a director upon exercise of stock options.
Preferred stock
At December 31, 2014 and 2013, the Company had 1,000,000 shares of preferred stock authorized. There were no shares issued and outstanding at December 31, 2014 and 2013.
Chinese subsidiaries dividends and statutory reserves
The payment of dividends by entities organized in China is subject to limitations. In particular, regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with PRC accounting standards and regulations. Based on People’s Republic of China (PRC) accounting standards, our Chinese subsidiaries are also required to set aside at least 10% of after-tax profit each year to their general reserves until the accumulative amount of such reserves reaches 50% of the registered capital. As of December 31, 2014 and 2013, statutory reserves aggregating approximately $35,000 were recorded in the Company’s consolidated balance sheets. These reserves are not distributable as cash dividends. In addition, they are required to allocate a portion of their after-tax profit to their staff welfare and bonus fund at the discretion of their respective boards of directors. Moreover, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Distribution of dividends from the Chinese operating companies to foreign shareholders is subject to a 10% withholding tax.
F-23
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE O- OPTION PLANS
1999 Stock Option Plan
In July 1999, the Company’s Board of Directors approved the 1999 Stock Option Plan (“the 1999 Plan”), for which the Company reserved an aggregate of 2,000,000 shares of common stock. The 1999 Plan provides that a committee of the Board of Directors of the Company will administer it and that the committee will have full authority to determine the identity of the recipients of the options and the number of shares subject to each option. Options granted under the 1999 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant (or in the case of incentive stock options granted to any individual principal stockholder who owns stock possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the committee but in no event shall exceed ten years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option. In July 2000, the Company’s Board of Directors increased the number of shares authorized for issuance under the 1999 Plan by 1,000,000 shares to 3,000,000 shares. In December 2001, the Board of Directors of the Company increased the number of shares authorized for issuance under the 1999 Plan by 2,000,000 shares to 5,000,000 shares.
The term for which options may be granted under the 1999 Plan expired July 12, 2009.
During the year ended December 31, 2014, options to purchase 90,000 shares of common stock under the 1999 Plan at an exercise price of $1.11 were retired.
2004 Stock Option and Stock Issuance Plan
In October 2004, the Company’s stockholders approved the 2004 Stock Option and Stock Issuance Plan (“the 2004 Plan”), for which the Company reserved an aggregate of 2,500,000 shares of common stock. The 2004 Plan is divided into two separate equity programs: (i) the Option Grant Program under which eligible persons (“Optionees”) may, at the discretion of the Board of Directors, be granted options to purchase shares of common stock; and (ii) the Stock Issuance Program under which eligible persons (“Participants”) may, at the discretion of the Board of Directors, be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.
Options granted under the 2004 Plan shall be non-qualified or incentive stock options and the exercise price is the fair market value of the common stock on the date of grant except that for incentive stock options it shall be 110% of the fair market value if the Optionee owns 10% or more of our common stock. The term of any option may be fixed by the Board of Directors or committee but in no event shall exceed ten years from the date of grant. Stock options granted under the 2004 Plan may become exercisable in one or more installments in the manner and at the time or times specified by the committee. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option. The term for which options or stock may be granted under the 2004 Plan expired July 12, 2014.
Under the stock issuance program, the purchase price per share shall be fixed by the Board of Directors or committee but cannot be less than the fair market value of the common stock on the issuance date. Payment for the shares may be made in cash or check payable to us, or for past services rendered to us and all shares of common stock issued thereunder shall vest upon issuance unless otherwise directed by the committee. The number of shares issuable is also subject to adjustments upon the occurrence of certain events, including stock dividends, stock splits, mergers, consolidations, reorganizations, recapitalizations, or other capital adjustments.
F-24
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The 2004 Plan provides that a committee of the Board of Directors of the Company will administer it and that the committee will have full authority to determine and designate the individuals who are to be granted stock options or qualify to purchase shares of common stock under the 2004 Plan, the number of shares to be subject to options or to be purchased and the nature and terms of the options to be granted. The committee also has authority to interpret the 2004 Plan and to prescribe, amend and rescind the rules and regulations relating to the 2004 Plan.
During the year ended December 31, 2014, options to purchase 287,864 shares of common stock under the 2004 Plan at exercise prices ranging from $0.22 to $0.58 were retired.
2010 Stock Option and Stock Issuance Plan
On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company. The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.
The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.
The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options. The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value). The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant. Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.
During the year ended December 31, 2013, 85,000 restricted shares of common stock were granted under the 2010 Plan to employees of the Company, all of which vested immediately. As of December 31, 2013, 105,000 additional shares were forfeited and 204,662 additional shares were withheld for withholding taxes.
During the year ended December 31, 2014, 1,090,000 restricted shares of common stock were granted under the 2010 Plan to employees, officers, and directors of the Company, vesting at various times through September 2017.
No options were issued under the 2010 Plan during the years ended December 31, 2014 and 2013.
2013 Stock Option and Stock Issuance Plan
On October 30, 2013, the Board of Directors approved the 2013 Stock Plan (the “2013 Plan”) for officers, directors, employees and consultants of the Company. The stock issuable under the 2013 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2013 Plan is 7,500,000 shares.
The 2013 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.
F-25
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
During the year ended December 31, 2014, 290,000 restricted shares of common stock were granted under the 2013 Plan to employees of the Company, vesting at various times through September 2017 and 30,012 shares were withheld for withholding taxes.
No options were issued under the 2013 Plan during the years ended December 31, 2014 and 2013.
Stock option activity under all the plans for the years ended December 31, 2014 is summarized as follows:
| Outstanding Options | ||||||||||||||||
|
Shares Available for Future Issuance
|
Number of Shares
|
Range of Exercise Price per Share
|
Weighted Average Exercise Price
|
|||||||||||||
|
Balance at December 31, 2013
|
785,224 | 1,779,776 | $ | 0.08 - $1.11 | $ | 0.22 | ||||||||||
|
Options granted
|
- | |||||||||||||||
|
Options exercised
|
- | (450,000 | ) | $ | 0.08 | |||||||||||
|
Options canceled under 1999 Plan
|
- | (90,000 | ) | $ | 1.11 | |||||||||||
|
Options canceled under 2004 Plan
|
- | (287,864 | ) | $ | 0.33 | |||||||||||
|
Expiration of 2004 Stock option plan
|
(785,224 | ) | ||||||||||||||
|
Balance at December 31, 2014
|
- | 951,912 | $ | 0.12 - $0.58 | $ | 0.17 | ||||||||||
The following table summarizes information about stock options outstanding and exercisable at December 31, 2014:
| Options Outstanding | Options Exercisable | |||||||||||||||||||||
|
Number Outstanding at December 31, 2014
|
Weighted Average Remaining Contractual Life (yrs.)
|
Weighted Average Exercise Price
|
Number Exercisable at December 31, 2014
|
Weighted Average Exercise Price
|
||||||||||||||||||
|
Range of Exercise Prices
|
||||||||||||||||||||||
| $ | 0.12 - $0.58 | 951,912 | 2.0 | $ | 0.17 | 951,912 | $ | 0.17 | ||||||||||||||
The following table summarizes non-vested common shares for the year ended December 31, 2014:
|
Shares Available for Future Issuance
|
Unvested shares
|
Weighted Average Grant Date Fair Value
|
||||||||||
|
Balance at December 31, 2013
|
8,591,222 | 375,000 | $ | 0.29 | ||||||||
|
Granted
|
(1,380,000 | ) | 1,380,000 | $ | 0.30 | |||||||
|
Vested
|
(1,159,988 | ) | $ | 0.32 | ||||||||
|
Forfeited
|
30,012 | (30,012 | ) | $ | 0.19 | |||||||
|
Balance at December 31, 2014
|
7,241,234 | 565,000 | $ | 0.27 | ||||||||
The aggregate intrinsic value of options outstanding and currently exercisable was $30,000 at December 31, 2014. There were 75,091,484 remaining authorized shares of common stock after reserves for all stock option plans.
F-26
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE P – BUSINESS COMBINATION
On August 6, 2014 the Company acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone) for cash and notes of Chinese Yuan RMB13,250,000 (approximately $2,151,000 at the acquisition date). The notes totaling RMB6,250,000 (approximately $1,015,000) are payable one year from the closing date with interest at the rate of 5% per annum. Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system. The primary purpose of the acquisition was to acquire ownership of the developed product including CFDA clearance as well as these patents and intellectual property.
The operating results of Genwell from August 6, 2014 to December 31, 2014 are included in the accompanying consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2014. The accompanying consolidated balance sheet at December 31, 2014 reflects the acquisition of Genwell effective August 6, 2014.
In accordance with Accounting Standards Codification 805, Business Combinations, the total purchase consideration is allocated to the net tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at August 6, 2014 (the acquisition date). The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The following table summarizes the estimated fair values of the net assets acquired:
| (in thousands) | ||||
|
Cash and cash equivalents
|
$ | 113 | ||
|
Accounts receivable and other current assets
|
2 | |||
|
Property and equipment
|
3 | |||
|
Intangible assets
|
2,033 | |||
|
Net assets acquired
|
$ | 2,151 | ||
During the year ended December 31, 2014, the Company expensed $8,000 of acquisition-related legal costs. The costs are included in the line item Selling, General & Administrative costs in the accompanying consolidated statements of operations and comprehensive income (loss). The amounts of revenue and net loss of Genwell included in the Company’s consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2014 was $0 and $29,000, respectively. Genwell is not expected to report future revenue as the sales of its principal product, MobiCareTM will be through Biox. Genwell may engage in research and product development activities in the future. The following unaudited supplemental pro forma information presents the financial results as if the acquisition of Genwell had occurred January 1, 2013:
| (in thousands) | ||||||||
|
Year ended
|
Year ended
|
|||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Revenue
|
$ | 34,981 | $ | 32,890 | ||||
|
Net income (loss)
|
1,048 | (1,508 | ) | |||||
|
Basic earnings (loss) per share
|
$ | 0.01 | $ | (0.01 | ) | |||
|
Diluted earnings (loss) per share
|
$ | 0.01 | $ | (0.01 | ) | |||
An adjustment was made to the unaudited pro forma financial information to reflect the acquisition-related costs in the year ended December 31, 2013.
F-27
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE Q- INCOME TAXES
As of December 31, 2014, the recorded deferred tax assets were $18,544,000, reflecting a decrease of $497,000 during the year ended December 31, 2014, which was offset by a valuation allowance the same amount. The Company also recorded a net deferred tax liability of $112,000 as of December 31, 2014 and 2013, which arose from pre-acquisition FGE operations, primarily related to revenue recognized for book prior to recognition for tax.
The Company’s deferred tax assets are summarized as follows:
| (in thousands) | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
Net operating loss carryforwards
|
$ | 16,014 | $ | 17,155 | ||||
|
Depreciation and amortization
|
219 | 136 | ||||||
| Stock-based compensation | 33 | 21 | ||||||
|
Allowance for doubtful accounts
|
14 | 66 | ||||||
|
Reserve for obsolete inventory
|
301 | 289 | ||||||
|
Tax credits
|
381 | 370 | ||||||
|
Expense accruals
|
315 | 175 | ||||||
|
Deferred revenue
|
1,267 | 829 | ||||||
|
Total gross deferred taxes
|
18,544 | 19,041 | ||||||
|
Valuation allowance
|
(18,544 | ) | (19,041 | ) | ||||
|
Net deferred tax assets
|
$ | - | $ | - | ||||
The activity in the valuation allowance is set forth below:
| (in thousands) | ||||||||
|
2014
|
2013
|
|||||||
|
Valuation allowance, January 1,
|
$ | 19,041 | $ | 18,147 | ||||
|
Change in valuation allowance
|
(497 | ) | 894 | |||||
|
Valuation allowance, December 31,
|
$ | 18,544 | $ | 19,041 | ||||
At December 31, 2014, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $40 million expiring at various dates from 2019 through 2033. Approximately $0 million and $4.4 million of net operating loss carryforwards expired in the years ended December 31, 2014 and 2013, respectively.
Income tax expense for the year ended December 31, 2014 was $127,000 and consisted mainly of federal alternative minimum taxes and state taxes. The Company recorded an income tax benefit of $58,000 for the year ended December 31, 2013 arising from a Federal refund of $97,000 related to a prior period amended return, partially offset by $52,000 in foreign income tax expense.
Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section 382 of the Internal Revenue Code provides, in general, that if an “ownership change” occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the “Section 382 Limitation” for each year (generally, the product of the fair market value of the corporation’s stock at the time of the ownership change, with certain adjustments, and a specified long-term tax-exempt bond rate at such time). The Company’s ability to use its loss carryforwards will be limited in the event of an ownership change.
F-28
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following is a reconciliation of the effective income tax rate to the federal statutory rate:
| For the year ended | ||||||||
|
December 31, 2014
|
December 31, 2013
|
|||||||
|
%
|
%
|
|||||||
|
Federal statutory rate
|
34.00 | 34.00 | ||||||
|
State income taxes
|
6.00 | 6.00 | ||||||
|
Change in valuation allowance
|
||||||||
|
relating to operations
|
- | - | ||||||
|
Utilizations of net operating loss carryforward
|
(40.00 | ) | (40.00 | ) | ||||
|
Foreign taxes
|
2.28 | 4.32 | ||||||
|
Alternative minimum tax
|
4.28 | (8.37 | ) | |||||
|
Other
|
3.58 | (0.77 | ) | |||||
| 10.14 | (4.82 | ) | ||||||
The foreign tax effective rate decreased mainly due to lower taxable income at Biox. The alternative minimum tax (AMT) rate increased due to the change from a taxable loss to taxable income in the year ended December 31, 2014, and to a Federal AMT refund on an amended prior period return recognized in the year ended December 31, 2013.
NOTE R- COMMITMENTS AND CONTINGENCIES
Sales representation agreement
In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015. In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.
Facility Leases
On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement, which expired in August 2012. In September 2012, the term of the lease was extended for an additional three years. The Company also leases offices in New York City under a five-year agreement expiring May 2017. FGE leases facilities in Wuxi, China, pursuant to leases expiring in December 2015 and March 2018, and a facility in Foshan, China, pursuant to a lease that expires in April 2016.
Vehicle Lease Agreement
In June 2011, the Company began taking deliveries under a closed-end master lease agreement for the provision of vehicles to the sales team of its Sales Representation segment. Vehicles obtained under the terms of the agreement are leased generally for a 36-month term, and payments are fixed for each year of the agreement, subject to readjustment at the beginning of the second and third year.
F-29
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Future rental payments under these operating leases aggregate approximately as follows:
For the years ended December 31,
| (in thousands) | ||||||||||||||||
|
Vehicles
|
Facilities
|
Equipment
|
Total
|
|||||||||||||
|
2015
|
$ | 288 | $ | 225 | $ | 34 | $ | 547 | ||||||||
|
2016
|
206 | 96 | 12 | 314 | ||||||||||||
|
2017
|
93 | 66 | - | 159 | ||||||||||||
|
2018
|
- | 12 | - | 12 | ||||||||||||
|
2019
|
- | - | - | - | ||||||||||||
|
Total
|
$ | 587 | $ | 399 | $ | 46 | $ | 1,032 | ||||||||
Rental expense for all operating leases totaled approximately $620,000 and $646,000 for the years ended December 31, 2014 and 2013, respectively.
Employment Agreement
On March 21, 2011, the Company entered into an Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, for a three-year term ending on March 14, 2014. The agreement was amended in 2013 to provide for a continuing three-year term, unless earlier terminated by the Company, but in no event can extend beyond March 14, 2019. The Employment Agreement currently provides for annual compensation of $275,000. Dr. Ma shall be eligible to receive a bonus for each fiscal year thereafter during the employment term. The amount and the occasion for payment of such bonus, if any, shall be at the discretion of the Board of Directors. Dr. Ma shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.
Litigation
The Company is currently, and has been in the past, a party to various routine legal proceedings incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
Foreign operations
During the years ended December 31, 2014 and 2013, the Company had and continues to have operations in China. Operating transactions in China are denominated in RMB, which is not freely convertible into foreign currencies. Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, and other factors. The occurrence of any of these risks, if severe enough, could have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.
Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions. There are many tax jurisdictions each of which may have changing tax laws. Applicable taxes include value added taxes (VAT), corporate income tax, and social (payroll) taxes. Regulations are often unclear. Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest. These facts create risks in China.
F-30
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE S- 401(K) PLAN
In April 1997, the Company adopted the Vasomedical, Inc. 401(k) Plan to provide retirement benefits for its employees. As allowed under Section 401(k) of the Internal Revenue Code, the plan provides tax-deferred salary deductions for eligible employees. Employees are eligible to participate in the next quarter enrollment period after employment. Participants may make voluntary contributions to the plan up to 80% of their compensation. In the years ended December 31, 2014 and 2013 the Company made discretionary contributions of approximately $85,000 and $62,000, respectively, to match a percentage of employee contributions.
F-31